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Summarv
Asthma is the most commoniy reported respiratory disease in clinical practice, affecting both
children and aduits (1). This disease is characterized by reversible airflow obstruction, increased
bronchial responsiveness, and airway inflammation (2). lt has been shown that persistent inflammation of
the airways can lead to chronic and possibly irreversible changes that affect the airway physiological
response to different stimuli (3). Over the last twenty years, cysteinyl leukotrienes (cys-LT) have been
shown to be potent bronchoconstrictor agents and important inflammatory mediators in the
pathophysiology 0f both acute and chronic asthma (1). Leukotrienes (LI) can induce smooth muscle
contraction, increase vascular permeabiiity, stimulate mucus secretion and recruit eosinophils into the
lungs (4). A number of activated inflammatory cells (i.e. mast cells and eosinophiis) can release cys-LTs
(4) and it has been shown that cys-LTs can collaborate with cytokines, namely Interieukin (lL)-5, in the
recruitment of eosinophils into the asthmatic airways (5), suggesting an autocrine cys-LT pathway
mediating the asthma phenotype. IL-5, alone, is a very important cytokine in asthma. IL-5 s increased in
the lungs of allergic and nonallergic asthmatics (6). Intra-tracheal administration of IL-5 ta human
asthmatics or to sensitized animais with the characteristics of atopic asthmatics increases the airway
response (7,8).
It s clear that enhanced cell-mediated immunity is an important char.açteristic of asthmatics. This
immunity s centralized around the activity of activated T lymphocytes. Activated lymphocytes are present
and increased in the airways of patients with asthma (9). The first part of my project studied the
reiationship between LIs and ceil-mediated immunity. By pre-treating sensitized BN rats with interleukin
(IL)-2, a T celI growth factor, these animais wiii have upreguiated cellular immunity with increased
inflammatory cells in the lung lavage and increased airway response ta antigen (10), but bile LI
production after antigen challenge in these animais has been previously shown ta be comparable ta
contrais (11). My hypothesis is that upreguiated cellular immunity creates a state of heightened sensitivity
to leukotrienes, which can be measured by assessing the response 0f the airways ta ieukotriene D4. As
weII, I hypothesize that blocking the cys-LT1 receptor with Monteiukast wiil alter the effects of IL-2 on the
late airway response and possibly affect cytokine production in the lungs.
2The second part of my thesis examined whether IL-5 can cause the characteristics of asthma in
animais that are considered normai. For these experiments I studied rats that do not develop the early or
late airway response after sensitization and antigen challenge. I hypothesize that intra-tracheal
administration of IL-5 can affect airway cholinergic responsiveness, the early and late airway response,
lung resistance, and airway inflammation in these rats. At the same time, it wouid be important to see if
these effects caused by IL-5 could be reversed by the anti-IL-5 monoclonal antibody (TRFK5).
My results show that there is a iink between ceII-mediated immunity and the leukotriene pathway.
Upregulation of the immune response with IL-2 increases the sensitivity of the airways to LTs. As well,
Montelukast inhibits the IL-2-mediated late airway response and modulates cytokine mRNA production
after antigen challenge, namely a decrease in Th2 cytokines (IL-4 and IL-5) and an increase in Thi
cytokine (IFN-y). However, IL-5 administered to normal controis is unable to cause many of the
physiologic and inflammatory characteristics of asthma (i.e early and late airway response and lung
eosinophilia after challnge, respectively), but the cytokine can trigger airway hyperresponsiveness to
methacholine, as welI as increase baseline lung resistance 20 hours after antigen challenge. Moreover,
Th2 cytokine mRNA expression is increased in the Iungs of IL-5 treated animais. In conclusion, the
information that is presented in this thesis establishes a link between cell mediated immunity and the
leukotriene pathway. I also show that one mediator is not sufficient to induce ail the physiological changes
that are present in asthma. (Keywords: Asthma, Cysteinyl-Leukotrienes, Interleukin-5)
3Résumé
L’asthme est la maladie respiratoire la plus rencontrée en pratique médicale clinique aussi bien
chez l’enfant que chez l’adulte (1). Cette maladie est associée à une obstruction réversible du flux d’air,
à une augmentation de la réactivité bronchique, ainsi qu’à une inflammation des voies respiratoires (2).
Il a été démontré qu’une inflammation persistante des voies respiratoires peut devenir chronique et
entraîner des changements irréversibles affectant la réponse physiologique des voies respiratoires face à
différents stimuli (3). Durant les deux dernières décennies, il a été démontré que les leukotriènes
cysteinyleês (cys-LT) sont des agents broncho-constricteurs ainsi que d’importants médiateurs
inflammatoires impliqués dans la physiopathologie de l’asthme chronique et de l’asthme aigu (1). Les
leucotriènes (LT) peuvent induire la contraction des fibres musculaires lisses, l’augmentation de la
perméabilité vasculaire, la stimulation de la sécrétion de mucus, ainsi que le recrutement des
éosinophiles dans les poumons (4). Plusieurs cellules inflammatoires activées (ex. mastocytes et
éosinophiles) peuvent libérer les cys-LT (4). lI a d’ailleurs été démontré que les cys-LT peuvent interagir
avec les cytokines, notamment l’interleukine (lL)-5, pour recruter les éosinophiles aux voies respiratoires
des asthmatiques (5). Il existe donc potentiellement une voie autocrine de la cys-LT promouvant le
phénotype de l’asthme. A elle seule, IL-5 est une cytokine très importante dans l’asthme. Ainsi, la
concentration d’IL-5 est augmentée dans les poumons des asthmatiques allergiques et non-allergiques
(6). L’administration intra-trachéale d’IL-5 augmente la réactivité des voies respiratoires et ce tant chez
les humains asthmatiques que chez les animaux sensibilisés servant de modèles de l’asthme atopique
(7,8).
Il est maintenant clair que l’augmentation de l’immunité cellulaire est une caractéristique
importante chez les patients asthmatiques. Cette immunité est centralisée autour de l’activité des
lymphocytes T activés. En effet, les lymphocytes T activés sont présents et augmentés dans les voies
respiratoires des patients asthmatiques (9). La première partie de mon projet étudie la relation entre les
LT et l’immunité cellulaire. L’interleukine(lL)-2, un facteur de croissance des cellules T, administrée en
pré-traitement à des rats Brown Norway sensibilisés, à pour effet de stimuler l’immunité cellulaire et
augmenter les cellules inflammatoires du lavage broncho-alvéolaire. Par conséquence, il a été démontré
que la réponse des voies respiratoires â l’antigène est augmentée (10), mais que la production du LT
4chez ces animaux demeure comparable aux groupes contrôles (11). La première partie de ma thèse
étudie l’hypothèse que lorsque l’immunité cellulaire est amplifiée, cela crée une augmentation de la
sensibilité des voies respiratoires aux LT, qui peut être mesurée en testant la réactivité des voies
respiratoires à la LTD4. En plus, mon hypothèse est que le blocage du récepteur de la cys-LT1 avec le
Montelukast (MK-0476) altérera l’effet de ‘IL-2 sur la réponse tardive des voies respiratoires et affectera
possiblement la production de cytokines dans les poumons.
La deuxième partie de ma thèse vérifie si l’administration de l’lL-5 peut causer des changements
caractéristiques de l’asthme, chez les animaux considérés comme normaux. Pour ces expériences, j’ai
étudié des rats qui ne développent pas de réponse aigu ou tardive dans les poumons, suite à la
sensibilisation et à la provocation antigénique. Mon hypothèse est que l’administration intra-trachéale
d’IL-5 peut affecter la réponse cholinergique des voies respiratoires, la réponse aigu ou tardive des voies
respiratoires, la résistance pulmonaire, ainsi que l’inflammation des voies respiratoires, chez ces rats. En
même temps, il serait important de voir si ces effets causés par l’IL-5 peuvent être bloqués par l’anticorps
monoclonal anti-IL-5fTRFK5).
Mes résultats montrent qu’il existe un lien entre l’immunité cellulaire et la voie des LT.
L’augmentation de l’immunité cellulaire avec l’IL-2 augmente la sensibilité des voies respiratoires aux LT.
De plus, le Montelukast inhibe la réponse tardive causée par l’i L-2 et réUuj d’une part la production
d’ARN messagers particulièrement celles de l’lL-4 et l’lL-5 libérés par les cellules Th2 et d’autre part
augmente la production de l’IFN-y libéré par les cellules Thi. Par contre, l’administration d’IL-5 chez les
rats contrôles ne permet pas de reproduite plusieurs des caractéristiques physiologiques et
inflammatoires de l’asthme (i.e. réponse aigu et tardive des voies respiratoires et éosinophilie des
poumons respectivement), mais cette cytokine peut déclencher une hyper-réactivité des voies
respiratoires à la méthacholine, ainsi qu’augmenter la résistance pulmonaire de base, 20 heures après la
stimulation antigénique. De plus, l’expression des ARN messagers des cytokines de type Th2 est
augmentée dans les poumons des animaux traités à l’IL-5. En conclusion, les résultats présentés dans
cette thèse démontrent bien le lien entre l’immunité cellulaire et la voie de synthese des LT. De plus ces
résultats montrent qu’un seul médiateur n’est pas suffisant pour induire tous les changements
physiologiques présents dans l’asthme. (Mots Clés : Asthma, Leukotriènes-cysteinyleês, interleukine-5)
5Introduction
1.1.1 Epidemiology
Allergic disease in general and asthma in particular have become an increasing problem for
public health, especially in developed countries. Epidemiologic evidence suggests that the prevalence of
asthma has increased significantly, especially among children (12,13). Asthma affects 5 to 10% of the
population (14) and in the United States alone, asthma affects 14 to 15 million persons. It s the most
common cause for hospitalisation of children and it continues to be fatal. In the United States, an
estimated 5000 persons die of asthma per year (15).
Some scientists have questioned the validity of reports that suggest that the prevalence of
asthma is increasing considerably in the population as a whole. Their main argument is that the reported
increases are possibiy due to a greater awareness among physicians of the importance of asthma as a
cause of chronic respiratory symptoms, especially among children (16). This theory is understandable
because it is stiil true today that many chiidren with asthma receive other diagnoses (wheezy bronchitis,
spastic bronchitis, etc.). However recent surveys that have included objective measures of risk factors for
asthma, such as allergic sensitization and bronchial hyperresponsiveness (17) confirm that only a small
proportion of the observed increases in the prevalence of asthma are due to a shift in diagnostic labelling.
Most surveys of chiidren in Western countries have reported that the prevalence of asthma is higher in
boys with some male/female ratios exceeding 2 to 1 (18).
1.1.2 Risk Factors I Asthma Mechanisms
In recent decades, a number of studies have suggested that allergen exposure is the primary
cause of asthma, and that the global increases in asthma prevalence could be the result of increases in
exposure to aeroallergens (19). The hypothesized causal mechanism s that allergen exposure produces
sensitization and continued exposure leads to clinical asthma through the development of airway
responsiveness and inflammation (Figure 1). However, there is a distinction between factors that can
precipitate attacks (secondary causation of asthma) and those that increase the risk of developing
asthma (primary causation of asthma). It is welI established that allergen exposure is a secondary cause
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7cf asthma in that it can trigger asthma attacks in sensitized asthmatic subjects and that prolonged
exposure can lead to persistence cf symptoms (19). Other risk factors which precipitate attacks include
viral infections, cigarette smoke, atmospheric pollution, and stress (20). A factor that proiongs or
exacerbates asthma symptoms may thereby increase asthma prevalence even if it has no effect at ail on
the incidence cf asthma. The evidence linking specific allergen exposure to asthma is weak and, if the
association is causal, the population attributable risk appears te be small. Some researchers have
theorised that the prevalence of asthma s related more te the total burden cf aercaliergens than to
exposure to a particular allergen. An alternative explanation is that specific allergen exposure may net be
a major primary cause cf sensitisation or of asthma itself, but may determine the specificity of the
sensitisation in susceptible individuals.
Several studies have shown the adverse effects of ambient air pollution on respiratory health
(20,21,22,23). A major causative agent could be cutdccr air pollution, derived from cars and other
vehicles. Studies have demonstrated that urbanisation and high levels cf vehicle emissions 15 correlated
with increasing frequency cf pollen-induced respiratory allergy. Pollen grains or plant-derived
paucimicronic components carry allergens that can prcduce allergic symptoms. There is evidence that air
pollutants may promote airway sensitisaticn by increasing the allergenicity cf airbcrne allergens. By
affecting plant growth, air pollutants can affect both the amount cf pollen produced and the amount cf
allergenic proteins contained in pollen (24,25). Aercallergens released by pollen grains can be transferred
te other, small, non-biclcgical particles cf air pollution such as diesel exhaust particulate (DEP) acting as
biological aerocontaminants cf the inhaled air which can penetrate deep into the airways inducing allergic
symptoms in sensitized subjects (26). DEP aIse exerts an adjuvant immunclcgical effect on
Immunoglubulin(lg) E synthesis in atcpic subjects thereby influencing sensitization te airbcrne allergens
(27). Airway muccsal damage and impaired muccciliary clearance induced by air pollution may facilitate
the access cf inhaled allergens te the ceils cf the immune system. Despite evidence cf a correlation
between the increasing frequency cf respiratcry allergy and the increasing trend in air pollution, the link
and interaction is stili speculative.
Researchers have pcstulated that the recent increases in asthma prevalence cculd be due te an
increase in the level cf exposure te certain indoor aeroallergens (17). They reason that changes in the
8structure of modem homes have rendered them more impermeable to the outdoor environment, making
the inhabitants of these homes significantly more exposed to indoor allergens. In addition, it is suggested
that the use of certain materials for home construction and in furniture stimulates the gcowth of indoor
allergen sources such as house-dust mites. Also the modem tendency to keep cats and dogs inside
homes can also increase the risk of sensitization to allergens produced by these pets.
It is important to note than an individual’s response to allergen exposure depends on the source
and components, as wefl as climatic factors which can favour the accumulation of allergens at ground
level. Therefore, the effects of allergens on lung function depends on the environmental concentration of
the allergen, the duration of exposure and the total ventilation of exposed persons.
1.1.3. Hygiene Hypothesis
There has been a significant increase in the prevalence of allergic diseases over the past 2 ta 3
decades. There are also clear differences in the prevalence of allergy and asthma between rural and
urban areas within one country. For example, in Ethiopia, asthme is more prevalent in urban areas than in
rural villages (28), and asthma is more common in residents of urban Germany than in farmers living in
rural Bavaria (29). b explain these observations, environmental factors associated with more
industrialised and urban living have been studied intensively, but there is little consistent evidence ta
suggest that obvious tisk factors, such as increased exposure ta indoor allergens (such as endotoxin and
lipopolysaccharides (LPS)), pollution, or changes in diet and breastfeeding, could account for the rise in
atopic diseases. lndeed, it may be that endotoxin prevents the development of asthma (30). Another
category of environmental factors, childhood infections, shows an overwhelming and consistent negative
association with atopy and allergic diseases. Allergic sensitization is overrepresented among first-born,
but is less frequent in children from large families (31), and those attending day care (32), suggesting that
a frequent exchange of infections may have a protective effect (31). It has been proposed that the lack of
intense infections in industrialised countries due ta improved hygiene, vaccination, and use of antibiotics
may alter the human immune system such that it responds inappropriately ta innocuous substances. This
so-called “hygiene hypothesis” (31) has a particular immunological profile, specifically e unique balance
between type 1 (Thi, associated with bacterial and viral infections and autoimmune diseases) and type 2
9(Th2, associated with helminth infections and allergic diseases) immune responses (33). The theory is
that limited exposure to bacterial and viral pathogens during eariy childhood results in an insufficient
stimulation of Thi cells, which in turn cannot counterbalance the expansion of Th2 cells and results in a
predisposition to allergy.
Th2 responses are characterised by increased IgE to allergens, mastocytosis, and eosinophilia.
Helminths are prevalent in developing countries and lead to strong Th2 responses. Nevertheless,
helminth-infected populations show little signs of aliergic disorders. This difference may be explained by
the differences in exposure to pathogens. A high prevalence of chronic infections in developing countries
resuits in persistent immune challenge, with cycles of infection and inflammation, which is followed by the
triggering of anti-inflammatory molecuies to restrict immunopathology. This dynamic interaction educates
the immune system to establish a robust regulatory network, possibly the key to controlling allergic
diseases. Such a network would be weakly developed in industrialised countries with low pathogen load,
allowing inappropriate immunopathologic reactions to develop more readily.
The immunological explanation for the hygiene hypothesis has been influential in directing
strategies to prevent allergic diseases. Induction of allergen-specific Thi response by Bacille Calmette
Guerin (BCG) or DNA vaccination is being advocated on the basis of the promising results obtained in
experimental animaIs (34).
1.1.4 Genetics
The environmental modifications that are causing the increases in asthma are more likely to exert
their influences in individuals who have certain genetic backgrounds. Genetic susceptibility is defined as
the presence of polymorphisms in genes that determine that certain individuals are at increased risk of
developing those diseases. The genetic variations that predispose those to asthma were present in the
population long before the current epidemic started. However, in the absence of certain environmental
influences, these variations did not lead to the development of clinical illnesses in the past. Complex
diseases such as asthma and allergies are almost always the result of interactions between different sets
of genes and environmentai influences that, acting together with these genetic variations make these
complex diseases more likely.
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It is very difficuit to measure simultaneously ail the environmental influences that can interact to
determine asthma risk, and particularly to measure them at the time in which they are active. Therefore
several genome-wide screens for asthma and its associated or related traits have been carried out
(35,36,37,38,39,40,41). Most of these studies lack sufficient statistical power, but some have been
relatively consistent in reporting genetic linkage in the same chromosomal region. Therefore, these
genetic loci may contain major genes influencing atopy and asthma (42). The latter include genes within
the cytokine gene cluster on chromosome 5, 11, 12, and 16 as likely candidates that may contribute to
asthma and allergy development. In addition, these data support the invoivement of genes involved in
antigen presentation fMHC) and T ceil responses (43). Studies in identicai twins have convincingly
demonstrated that at least 50% of the susceptibility to asthma is determined by inherited predisposition
(44).
Some of these aforementioned candidate genes couid yieid new therapeutic approaches once
they are fully validated. It remains to be established whether there are functional polymorphisms in these
candidate genes that determine the severity of the disease phenotypes. These polymorphisms could be
the target of several therapeutic scenarios, including a reduction in gene expression or an elimination or
alteration in the protein of interest.
1.2. Asthma Characteristics
Asthma is often associated with atopy, a disorder characterized by sustained, inappropriate IgE
responses to common environmentai antigens (allergens) encountered at mucosal surfaces (45). Cross
Iinking of surface Fc receptors to aliergen-specific IgE is assumed to play a role in the pathogenesis of
atopic asthma (46). However, a minority of asthmatic individuals are not demonstrably atopic according to
conventional criteria, which has led to the suggestion that asthma may be divided clinically, and perhaps,
mechanisticaiiy, into atopic (extrinsic) and nonatopic (intrinsic) variants (47).
Intrinsic asthma is considered to be a distinct pathogenetic variant of asthma since, uniike
extrinsic asthma, patients with the disease are skin test-negative to common aero-allergens, and have
total serum IgE concentrations within the normai healthy range. As well, the celiular pattern for
eosinophils, neutrophils, T lymphocytes, and cytokines differs between atopic and non-atopic patients
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with asthma. In atopic asthmatics, the airway inflammation is characterized by high numbers of
eosinophils, mast celis, and T lymphocytes, whereas non-atopic asthmatics mainly display high number of
neutrophils and mast cells (48). IL-4 and IL-5 positive cells are found in higher numbers in atopic than in
non-atopic patients with asthme. There are also distinct structural alterations in the airway mucosa of
patients with atopic asthme that are flot found in non-atopic asthmatics.
Intrinsic asthma occurs in an older age group of people without any history of ellergy to
environmentaÏ factors (49). In contrast, extrinsic asthme usually develops in childhood, occurs often
seasonally and remains present throughout life, with periods 0f remission (50,51). Intrinsic asthma has a
preponderance to affect females and it is associated with nasal polyps and aspirin sensitivity (52,53).
Whereas some authors suggest that around 10% of asthmatics are intrinsic, a Swiss study found that a
third of total asthmatics are non-allergic (intrinsic)(53,54).
Ever since the first description of intrinsic asthma, there has been debate around the relationship
of this variant of the disease to atopy (53). One suggestion is that intrinsic asthma represents e form of
autoimmunity, or autoallergy, triggered by an infection since respiratory influenza-like illnesses often
precedes the onset. Some researchers suggest that intrinsic asthmatics are allergic to an as yet
undetected allergen and could therefore benefit from allergen avoidance, as previously demonstrated in
atopic asthmatics (55).
1.2.1 Early Airway Response ILate Airway Response
AI lergen challenge of sensitized atopic individuals results in an early response (ER), which in the
skin is seen as the immediate wheal and flare reaction, and after inhalation as e decrease in airway
caliber occurring within minutes (56). The eatly airway response (ER) occurs within minutes of inhalation
of antigen, lasts up to an hour, and is followed by a prompt return to baseline lung resistance (57) (Figure
2A). The ER is mediated by IgE antibodies, which are present on mast ceils and basophils. These
antibodies cross-link when in contact with allergen leading to degranulation of the cells and increased
microvascular permeability (58). Bronchoconstriction of the airways during the ER is induced by the
release of histamine, Ieukotrienes, eicosanoids, and possibly other bronchoconstrictive agents (59).
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The late airway response (LR) occurs 4 to 12 hours after antigen exposure and may persist long
after antigen exposure has ceased (60) (Figure 2E). In general, most atopic asthmatics develop both
responses (Figure 2C), although occasionally, only an early or a late response is encountered (61).
Airways of individuals experiencing the LR show increased edema and an infiltration with different
inflammatory cells, in particular eosinophils and T lymphocytes (62,63).
1.2.2 Airway Hyperresponsivness
Airway hyperresponsiveness fAHR) is characterized by an increase in the sensitivity and
reactivity of the airways to agonists, such as allergens, and the development of a lower threshold to
spasmogens that will hinder airflow (64). AHR occurs before the symptoms of the LR arise and can
remain after the symptoms have subsided (65,66). The type of physiological response s directly related
to the degree and method by which various antigens are presented to the immune system in the airways
of atopic asthmatics (67). Exposure to an antigen to which one is sensitized to may only cause an acute,
transient increase in airway hyperresponsiveness, however continuous exposure to an allergen may
cause an individual to reach a chronic state of airway inflammation and hyperresponsiveness (61).
Inflammation is flot always necessary for AHR to occur. Bronchoconstrictive agents such as histamine,
cholinergic agents and some -agonist blockers cause bronchospasm through smooth muscle contraction
without airway inflammation (61).
AHR occurs through neuronal mechanisms and inflammatory mediator release which affects the
sensitivity of the airways to stimuli and accordingly the amount of smooth muscle contraction.
Consequently, increased AHR leads to a decrease in airway diameter (68). The relationship between
inflammation and hyperresponsiveness in the airways is especially important during the LR. There s an
increased presence of inflammatory cells and mediators in the airways during the LR (69).
Type 2 T helper lymphocytes (Th2) orchestrate the inflammation and are crucial for the
development of AHR. Celis and molecules involved in T celI activation (dendritic cells, T celI receptor,
major histocompatability complex molecule, and costimulatory molecules) are also vital. There are at least
three pathways that lead to AHR. One is dependant on immunoglobulin E and mast celis, one on
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eosinophils and interleukin-5 (IL-5), and one on IL-13. Eosinophils are probably the most important
effector ceils of AHR.
The nature of the relationship between AHR and atopy (specific lgE to aeroallergens) is unknown
and one of the most important questions in asthma. It is clear from epidemiological studies that these two
abnormalities are Iinked. However, flot ail allergic (atopic) people have AHR and flot ail individials with
AHR are allergic. Furthermore, there is some suggestion that the risk factors for the two abnormalities
are different.
12.2.1. Airway Hyperresponsiveness in Humans
Researchers have long used stimuli, such as histamine and methacholine, to measure the level
of AHR in patients with asthma and in animal models. By instilling or nebulizing incremental doses of
these mediators to the airway, they are able to assess and to quantify the threshold of tolerance toward
non-specific irritant stimuli (70,71). AHR is often defined as a 20% fall in the FEV1 in response to a
provoking agent, such as histamine, methacholine, or hypertonic saline, and sometimes to exercise or
cold air hyperventitation. However a measure of AHR is not always considered to be a sign of asthma or
even of airway inflammation (72). The amount of AHR to cholinergic agonists correlates only with the
level of certain asthmatic symptoms such as wheezing and nocturnal cough and can give a limited
prognosis of the severity of an asthmatic attack (72). Airway hyperresponsiveness is not restricted to non
specific stimuli. AHR can occur in normal subjects following viral respiratory infection and can be present
in atopic non-asthmatic individuals, in patients with chronic obstructive pulmonary disease or cystic
fibrosis (73,74,75).
1.2.2.2. Airway Hyperresponsiveness in Animal Models
Airway responsiveness in the intact animal depends on tracheal smooth muscle airway
contractiiity, chest wall compliance, bronchiolar mucus plugging, airway fibrosis, and other factors (76).
AHR is a function of both airway hyper reactivity (an increased response to a given dose of
bronchoconstrictor) and airway hyper sensitivity (the ability to respond to a smaller dose of
bronchoconstrictor) (77).
There are three ways to measure AHR (78). The ex vivo technique examines the contractility of
dissected tracheal smooth muscle stimuiated by electricity or methacholine. The first in vivo method
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measures the airway pressure and lung resistance of an anaesthetised animal with an intratracheal and
intra-esophageal cannula (79). The second in vivo method uses unanaesthetised and unrestrained
animaIs in a plethysmography box to produce a mathematically derived parameter called the enhanced
pause (Penh) that reflects airway obstruction (78).
The ex vivo method differs from in vivo measurements because it neglects the effects of edema,
mucus, or chest wall recoil on airway narrowing. The first in vivo method requires the technique of trachea
and esophageal cannulations. The second in vivo method permits uninterrupted measurements, enabling
the evaluation of early and late phase bronchial response and the discernment of airway hyperreactivity
and airway hyperresponsiveness (80). Howevet, in some circumstances, the nasopharynx contributes
significantly to the total airway resistance with this method.
1.2.3 Airway RemodellinglObstruction
Asthma has traditionally been thought of as an entirely reversible disorder. However, a number of
studies have demonstrated that individuals with asthma experience an accelerated rate of respiratory
function deterioration (81). Patients with asthma can develop a physiological state characterized by
irreversible, or partially reversible, airway obstruction, and they manifest persistent AHR even after
prolonged corticosteroid therapy. The pathogenic mechanisms responsible for these findings are poorly
understood but they may be the resuit of structural changes, referred to as airway remodelling.
Remodelling in chronic asthmatic airways is characterized by waii thickening, subepithelial fibrosis,
mucous metapiasia, myofibroblast hyperplasia, vascular abnormalities, and myocyte hyperplasia and
hypertrophy (82).
7.2.3.1 Aiway walI thickening
Ail components cf the airway wall (inner, outer and total) have been reported to be thickened in
asthma. Many elements contribute to this response, including an increase in airway smooth muscle.
edema, ïnftammatory celI infiltration (Figure 3), glandular hypertrophy, and connective tissue deposition.
Compared to ncnasthmatic subjects, airway wall thickness is increased from 50% to 300% in cases cf
fatal asthma, and from 10% to 100% in cases of non-fatal asthma (83). The exact physiologic and
Figure 3: Photomicrographs of airway inflammation
(a) the airway submucosa (S) from a nonasthmatic
individual with few inflammatory celis, bar = 0.1 mm
(b) the submucosa from an individual with
fatal asthma with polymorphonuclear and
mononuclear celi infiltration, bar = 0.05 mm
Reprinted with permission from Holgate ST, Busse WW.,
Tnftammatory Mechanisrns in Asthma. Vol 117.
Marcel Dekker Inc.,NY, pg. 12, 2001.
• —
f .• ..• ..•..
••
‘•‘-..•_
s \
.
-
•:
•15
j
s.
t t
•55
‘••‘s
-u t
‘
sk’
4
4,
k
I
4d%
16
17
pathologic consequences of airway wall thickening are incompieteiy understood. Some models have
demonstrated that the thickening response reduces the amount of smooth muscle shortening required to
cause airway closure (84).
1.2.3.2 Basement Membrane Thickening
Collagen deposition beneath the basement membrane is described as “basement membrane
thickening” (85). This has been recognized as increased coilagen types III and V, as weli as matrix
components laminin and fibronectin along the basement membrane (composed of type IV collagen) (86).
Multiple factors have been associated with subepitheliai coilagen thickening including increased
frequency of asthma (87), longer duration of symptoms (88), airway hyperresponsiveness (89), increased
T lymphocyte and fibrobiast activity (90,91), epithelial damage (92), as well as mast ceil and eosinophil
infiltration (93). A possible mechanism is that growth factors reieased by cellular activity lead to increased
myofibroblast numbers and activation observed below the basement membrane (94) where they appeat
in relative abundance. Enhanced coilagen production by myofibroblasts and fibroblasts beyond the rate of
collagen breakdown will lead to increased deposition. Potentiaily, the increased airway rigidity may
contribute to mortality in asthma by reducing the maximal bronchodilator response. In addition, internai
mucosai edema may cause significant internai luminai narrowing, without allowing outward radial
expansion of the wall.
1.2.3.3 Smooth Muscle Hypertrophy/Hyperplasia
A 50-230% and 25-150% increase in the area of airway smooth muscle has been demonstrated
in fatal and nonfatal asthma, respectiveiy (83) (Figure 4). These findings imply that the increased smooth
muscle mass in some asthmatics may predispose to poorer iung function and a poorer response to a
severe attack. Presumably, the factors known to be trophic for smooth muscle growth act unopposed in
persistent airway inflammation. These inciude histamine, thrombin, thromboxane A2, and epidermal and
platelet-derived growth factor (95). The modeliing studies of Wiggs and colleagues have indicated that
shortening of inner airway walI smooth muscle by 40% may be sufficient to lead to airway closure (96).
Figure 4: Photomicrograph of airway smooth muscle
Reprinted with permission from Holgate ST, Busse WW.,
Inftammatory Mechanisrns in Asthma. Vol 117.
Marcel Dekker Inc.,NY, pg. 1$, 2001
(a) a nonasthmatic individual showing normal
airway smooth muscle (M), bar = 0.5 mm
(b) an individual with fatal asthma showing a
prominent layer of smooth muscle (M) surrounding
the folded airway mucosa, bar = 0.05 mm
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Moreover, the added thickness may account for the loss of dynamic expansion of deadspace seen during
inspiration in asthma (97).
1.2.3.4 Mucus Metaplasia
Mucus hypersecretion, epithelial mucus metaplasia, and airway obstruction due to bronchial
mucus plugging are well-documented features of chronic asthma and status asthmaticus (98).
Morphometric and immersion fixation studies demonstrate that the area of mucus glands is increased in
fatal and nonfatal asthma. Liquid and mucus can also f111 in the interstices and folds of the airway surface.
This could add to the forces tending to narrow the airway by amplifying the effect of muscle shortening
and increasing the surface tension at the air-liquid interface.
1.2.3.5 Airway Vascularity
The bronchial mucosa of endobronchial biopsies from mild asthmatics has been shown to contain
increased numbers of vessels per unit area (738 per mm2) (99). The increase in vascularity below the
basement membrane and adjacent to the musculature is potentially capable of causing further luminal
narrowing. Using anti-collagen type IV antibodies on biopsies from mild asthmatics, researchers have
found significantly more vessels overali and more vessels larger than 300 pm2 in asthmatic airways,
suggesting bronchial vasodilation in addition to angiogenesis. Canine models have demonstrated in vivo
correlation between airway thickening and airflow obstruction (100). This engorgement might also
contribute to the loss of airway distensibility seen in asthma (97).
1.3 Airway Inflammation
1.3.1 IgE
The secretion of IgE by B lymphocytes defines the allergic state, and the association between
allergy and asthma is well established (101). The percentage of asthmatic subjects defined as allergic
depends on whether subjects have a positive skin test to an aeroallergen in addition to elevated levels of
serum IgE. IgE binds to high or low affinity receptors (FceR) and CD23, respectively) on the surface of a
variety of effector celis, the most important of which are mast cells and basophils. The cognate antigen
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crosslinks IgE bound to high affinity receptors on mast cells and on basophils causing the celis to release
a variety of preformed and newly generated mediators that promote airway hyperresponsiveness, mucus
hypersecretion, and increases in vascular permeability. The early asthmatic response is clearly
dependant on IgE-mediated activation of mast cells through high affinity receptors (FceRI). Antigen
specific IgE responses are regulated by HLA class Il and T-ceIl receptors and involve T-B cognate
interaction while nonantigen-specific IgE response involve noncognate interaction of mast celis,
basophils, and T and B cells (102). IL-4 is the most important cytokine mediating IgE synthesis and
together with IL-13 plays a central role in the IgE-dependent allergic reaction.
The role of IgE in mediating an allergic airway reaction is confirmed by the finding that treatment
of allergic asthmatic patients with monoclonal anti-IgE antibodies attenuated airway eosinophilia,
increased the dose of allergen needed to provoke an early reaction, and reduced the mean maximum fali
in FEV1 during the early and late responses to allergen challenge (103). Therefore, IgE has a direct role in
mediating not only the ER, but also the LR.
While IgE-dependant inflammation plays a major part in allergic asthma, there are many
inconsistencies. One study has demonstcated that total IgE s a poor diagnostic indicator of respiratory
allergic disease (104) and in the African population serum levels of IgE have been reported to be higher
in nonasthmatics than in asthmatics (105). Moreover, IgE knockout mice when challenged with allergen
can elicit an inflammatory tesponse in the airway as weIl as airway hyperresponsiveness (106). Even the
syndrome of active anaphylaxis, with mast celi activation and mediator release can be displayed by both
ovalbumin (OVA) sensitized lgE’ and FceRI-deficient mice after intravenous challenge with OVA
(107,108). These studies cast a question mark on the precise role of IgE in allergic disease.
1.3.2 Eosinophils
The current view of the eosinophil is that t is a proinflammatory celI with substantial tissue
destructive potency. The biological activities exerted by the eosinophil are related to the products
released from its granules, including the eosinophil cationic protein (ECP) and the major basic protein
(MBP) (Figure 5) . These two potent cytotoxic proteins have the capacity to kiil both mammalian and non
mammalian celis, such as parasites, by making pores in celi membranes, which leads to osmotic lysis
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Figure 6: Eosinophil Cationic Protein (ECP)
Electron microscopic demonstration ofthe effect of eosinophil
cationic protein on cellular membranes which can produce pores
with an approximate diarneter of 5nm.
Photo courtesy ofDr. Per Venge, Uppsala University,
Uppsala, $weeden
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(Figure 6). The accumulation and activation of eosinophfls from the bone marrow to the lungs is
governed by the upregulation of adhesion molecules on lung endothelial celis and the production of
various cytokines and chemotactic molecules by mast cells and T cells. 0f these cytokines, IL-5 seems to
play a central roTe, because it regulates most aspects of eosinophil behaviour, such as growth, apoptosis,
adhesion, and secretion (109). Activation of the endothelium by cytokines such as IL-4 favours their
migration to the lungs by upregulating the expression of vascular ce!! adhesion molecule 1 (VCAM-1) on
endothelial cells (110).
Eosinophils differentiate within the bone marrow under the influence of GM-CSF, IL-3, and IL-5
(Figure 7). In response to allergic stimuli in the lung, the eosinophil pool in the bone marrow expands and
the number of eosinophils residing in the blood and at the site of allergen provocation increase markedly.
Circulating eosinophils are recruited into tissues following adhesion to endothelial celis expressing
specific adhesion molecules, including VCAM-1, which recognizes vascular leukocyte antigen-4 (VLA-4)
found on eosinophils, and ICAM-1 that binds CD11/CD18 molecules on a range of leukocytes types.
Eosinophils migrate in response ta chemoattractants, including Iipid mediators, complement components,
chemokines, and cytokines. Eosinophils express receptors for complement components C3a and C5a, for
chemokines including IL-8, RANTES fCCR-1) and eotaxin (CCR-3), for cytokines including IL-1, IL-2, IL-
3, IL-4, IL-5, IL-9, IL-16, GM-CSF, IFN-y, and TNF-Œ, and for immunoglobulins (1g) A, G, and E (high and
10w affinity) (111). Eosinophils are thus weII equipped ta respond ta a range of inflammatory stimuli.
Eosinophils are also an important source 0f inflammatory mediators. Among the lipid derivatives,
eosinophils have the capacity to produce an amount of leukotrienes comparable with that of mast cells
and basophils and higher than that of monocytes (Figure 7). Eosinophi!s also generate 15-HETE,
lipoxins, platelet-activating factor (PAF), and small amounts of thromboxane2 (TXA2) and prostaglandin2
(PGE2). The eosinophil specific granule contains MBP in its core, and ECP, EPO, and EDN in its matrix.
These granule-derived proteins have cytotoxic activity for helminths and are implicated in branchial
epithelial damage (112).
Early studies on post-mortem Iungs obtained from patients who died of asthma showed
significant eosinaphilia. Influx of eosinophilia into the branchoalveolar lavage (BAL) fluid was
demonstrated during the late response aher allergen challenge of atopic subjects, at a time when
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bronchial responsiveness is enhanced. In numerous clinical asthma studies, eosinophilia lias been
demonstrated in bronchial biopsies, induced sputum, BAL fluid, and blood of allergic and nonallergic
patients (113). Levels of MBP and ECP are elevated in lung tissue and BAL fluid obtained from
asthmatics, suggesting eosinophil activation (112). Eosinophil numbers in biopsies and BAL fluid
correlate with asthma symptom scores, Iung function (FEV1) and nonspecific AHR.
Although there is evidence of the eosinophil as a primary effector ceII leading to
bronchoconstriction, epithelial damage and AHR in clinical asthma, its contribution in individual subjects
may be highly variable (113). In several studies, a distinct proportion of patients with clinically significant
asthma had negligible counts of eosinophils in bronchial biopsies or BAL fluid. Correlations between
eosinophilia and AHR may be statistically significant, but individual patients may differ from this simple
relationship, with activated T cells sometimes showing stronger correlations with measures of disease
severity.
In contrast to wild-type litter mates, allergic IL-5 -I- mice do not generate eosinophilia in the blood
and bone marrow compartments in response to allergen provocation of the lung, and this greatly reduces
the level of eosinophils recru ited to the airways (114). However, mature eosinophils stiil reside in the
blood (albeit reduced numbers) and bone marrow compartments, indicating that baseline differentiation,
maturation, and subsequent extramedullary migration persist in the absence of IL-5 (114). Results
suggest that the primary role for IL-5 is in the promotion of peripheral eosinophilia in response to aHergic
stimulation.
1.3.3 Neutrophils
The neutrophil has only recently boen the target of considerable interest regarding asthma
pathogenesis. In recent years, the expansion of invasive studies to more severe forms of asthma, the
advent of sputum analysis, concerns regarding the eosinophil as the most important effector celi and an
appreciation of the properties intrinsic to the neutrophil, have Ied to an increased interest in this celI type.
The inflammatory products generated by the neutrophil range from cytokines, chemokines, and Iipid
mediators to reactive oxygen species, various proteases and growth factors (115). The most important of
26
these are IL-8, LTB4, and matrix metalloproteinase (MMP)-9. IL-8, a potent chemoattractant for
neutrophils, has been reported to be increased in asthmatic patients.
Neutrophils may predominate in the airways of patients with nocturnal asthma, sudden-onset fatal
asthma, acute exacerbations or severe asthma poorly controlled by high dose glucocorticoids (116).
Sputum analysis of asthmatics demonstrated that neutrophils were the prominent ceil in subjects with
severe asthma, as weIl as mild asthmatics. Although the sputum reflects pathology in the larger airways,
in both transbronchial biopsies and surgical evaluation of neutrophils in the small airways, there appears
to be an increase in neutrophils, with specific localization to the small airway inner wall (117).
It is not likely that the neutrophil plays any role in the acute bronchospasm associated with
asthma, given the profile of the mediators genetated by these celis. Neutrophils are more likely to be
involved in chronic inflammation, wound repair, and remodelling processes of asthma. The neutrophil is
well-known to be part of the wound repair processes in the skin, eyes, and blood vessels (118). Studies
indicate that the neutrophil may contribute to the fibrotic processes associated with asthma, particularly
the basement membrane thickening, through its production of TGF-13 and MMP-9. TGF-f3 has been
reported to be increased in bronchoalveolar fluid and in the celis of patients with asthma, with studies
showing that at least 50% of these TGF-Ç3 ceils are neutrophils (117). MMP-9 has also been reported to
be increased in asthma and in patients with status asthmaticus, but whether their source is the neutrophil
or not is difficuitto prove. (119).
Neutrophils have also been suggested to play a role in mucus production and secretion, both
prominent features in severe asthmatics. Several animal studies support a role for neutrophils and
neutrophil elastase in both the upregulation of MUC-5 mRNA and protein, and in the degranulation of
goblet cells (120,121). In animal models, removing the neutrophil appears to decrease mucus production
(122). As well, data suggest that the neutrophil might be an important mediator of airway caliber in
asthma but might not be an important mediator of bronchial hypersensitivity.
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1.3.4 Mast Ceils
Mast ceils are key cellular participants in allergic disease (Figure 8). Their potential role in
asthma was recognized early on with the identification of these ceils as major sources of the
spasmogenic mediator histamine. The activation of mast cells is known to release a range of potent
mediators of inflammation, including proteoglycans (heparin, chondroitin sulphate), proteases (tryptase,
chymase), cytokines (IL-4, GM-CSF) and lipid mediators such as prostaglandins(PG) D2 and LIC4 which
leads to bronchoconstriction. Ihese products may be stored in the prominent secretory granules of these
ceils and are released following celI activation. Mast ceils can be stimulated to degranulate by cross
linking allergen-specific IgE bound to high-affinity IgE receptors on the ceIl membrane. Mast cells express
approximately 300 000 high affinity IgE receptorslcell, but cross-linking only 100 receptors will result in
detectable responses (123). Mast cells may also be activated by diverse stimuli acting through other
receptors (specific allergens, adenosine, neuropeptides, opiates). Histamine, the best studied of mast celi
products, accounts for 5-10% of mast ceil granule content, and is stored in association with
proteoglycans. Histamine receptor stimulation resuits in smooth muscle contraction, increased vascular
permeability, and prostaglandin generation.
In the airways, mast cells are abundant in the mucosa. Ihey may also be ptesent in the
submucosa, particularly in the vicinity of mucus glands, and small numbers are free in the lumen, where
they are weil placed to respond to inhaled allergens. Mast celi derived mediators have been found in
lavage fluid from patients with asthma, supporting the role of these cells in the immediate or early allergic
reaction in asthma (123). When aHergen challenge preceded BAL, increases were documented for
histamine, LTD4, PGE2, and tryptase (123). Ihe role of mast ceNs in the late allergic response has been
more difficult to resolve. However, they are thought to play a key role in the development of the chronic
inflammatory phase through their production of cytokines and chemotactic factors that lead to the
recruitment 0f other celi types such as eosinophils (107).
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7.3.5 Macrophages
Monocytes and macrophages are ceils of the mononuclear phagocyte lineage and are found in
essentially every human tissue and body cavity. They derive from immature bone marrow precursors that
are released into the blood, where they are termed monocytes, and are then recruited to tissues where
they undergo tissue-specific terminal differentiation to macrophages. Macrophages exhibit a wide range
of functions, ranging from the capacity to phagocytose and kili microorganisms, to presentation of antigen
to T ceils and the release of large quantities of numerous soluble mediators (Figure 9).
Macrophages can be activated via the cross-linking of surface IgE bound to the high and low
affinity receptors for IgE. Activation through the 10w affinity IgE receptor, FceRll, leads to release of
soluble mediators, including proinflammatory cytokines and leukotriene B4 and C4 (124,125). Recent
studies have shown greatly increased efficacy by monocytes of antigen uptake and presentation to T ceils
via the high affinity IgE receptor, FceRl (126).
The pulmonary immune system represents a highly specialized and unique environment. Despite
containing the greatest proportion of memory T ceNs of any compartment of the body and having
continuaI exposure to foreign antigen in the air we breathe, littie or no immune activation is observed in
the Iungs of normal healthy individuals. Such activation would be likely to result in damage to the fragile,
permeable epithelial lining of the airways that permits gaseous exchange to occur, a primary and
essential function of the lung. Macrophages play a central role in preventing such activation from
occurring. Alveolar macrophages, located on the distal side of the epithelial lining of the ung, have a
highly phagocytic and microbicidal nature. They are responsible for eliminating inhaled particulate
antigens, such as microbes, allergens, and toxic substances, by physical means, namely ingestion
followed by degraduation and elimination. In doing so, inadvertent and unnecessary immune activation is
prevented.
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1.3.6 Dendritic Ceils
Over the iast 25 years, it has become clear that dendritic celis (DC) are the major antigen
presenting ceNs inducing the primary immune response in vivo (127). DCs capture antigens in the
peripheral tissues and carry it into the T celi area of draining lymph nodes, where naive T lymphocytes
are continuousiy re-circulating in search of specific antigens. Aithough many celi types such as
macrophages and eosinophils have been shown to transport antigens into the draining nodes, the
directed migration into the T celi area is a specialised function of DCs (128). The capacity to uptake
antigens 15 a feature of immature DCs residing in peripheral tissues, and is largely lost during the
migration of DCs into the draining lymph nodes. This way, immature DCs effectively make a “snapshot” of
the antigens present in a peripheral inflammatory site. Interactions in the draining Iymph noUes are
important for clonai expansion, differentiation, and avoidance of anergy in T ceNs.
Lung DCs have an immature phenotype, specialized for uptake and recognition of inhaled
antigen, but not yet capable of stimulating naive T celis, because they lack co-stimulatory molecuies
(129,130,131,132). When antigen is encountered in an inflammatory context, there is a dramatic change
in the behaviour of the DC5, a process called maturation. Upon recognition of foreign antigens, DCs have
to migrate from the periphery to the draining Iymph nodes against the chemotactic gradient that attracts
immature DCs. Therefore, upon recognition of antigen, DCs lose responsiveness to iung-expressed
chemokines, e.g. by downregulation of the CCR6 receptor, but at the same time increase the expression
of the CCR7 molecule, which directs the DCs towards the lymph noUes (133). The migration of airway
DCs in response to an immunogenic stimulus is rapid and within 12h, lung derived DCs can be traced in
the T ceil area of the mediastinai Iymph nodes of the iung (1 28,134,135).
The increased presence of DCs in the airways of atopic asthmatics and allergen exposed animais
suggests that DC5 have a critical contribution to the disease pathogenesis (136,137,138). They have
been associated with Th2-dependant sensitization Ieading to eosinophiihc airway inflammation (139).
Reducing the number of DC5 eithet experimentaiiy or by inhaied corticosteroids is associated with a
reduction in eosinophillic airway inflammation (140).
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7.3.7 Lymphocytes
It is widely believed that T celis acting via the release of cytokines are central regulators 0f human
airway inflammation and in turn, the abnormalities in lung patho-physiology in asthma such as wide
spontaneous fluctuations in airway caliber, bronchial hyperreactivity and airflow obstruction are the direct
consequence of inflammation 0f the bronchial mucosa. Th2-based T cells (T ceil populations able to
secrete IL-4, IL-5, IL-6, IL-9, and IL-13) are dominant effector ceils in the pathogenesis of asthma.
Lymphocytes are activated by antigen-presenting celis and adopt functional phenotypes under instruction
from soluble and physical signaIs that they receive during antigen presentation. They expand by
proliferation, reaching sites of inflammation under the instruction of patterns of chemokines and adhesion
molecules where, as armed effector cells, they affect other leukocytes. The abbreviations Thi (T helper
celi type 1) and Th2 (T helper celI type 2) have been classically referced to CD4 c3 TCR T ceil subsets
that are crucial to both the innate and adaptive immune systems. Other lymphocytes have been reported
to produce Thlrrh2-type subsets including y3 TCR T ceNs (141,142), and CD8 c43 TCR T cells (143).
Multiple Th forms have been described (e.g. Thi, Th2, Thp, ThO, and Th3) (141,144,145,146,147), and
the terms naive, effector, and memory are often mentioned within the same context (141,144,148,149).
Antigen-naive T cells are designated Thp for precursor of T helper celI (144). Antigen exposure to a Thp
ceil results in the selective maturation to either Thi or Th2 ceils. The Th phenotypes are characterized by
the cytokines they produce. The first Th ceil types characterized were mouse Thi and Th2 cells. Mouse
Thi ceils secrete IFN-y, while Th2 ceils secrete IL-4 (150). In humans, Thi cells have been identified to
secrete IFN-y, while Th2 ceils secrete IL-4 and IL-5 (151). Subsequent studies have established that Thi
ceils produce IFN-y, TNF-f3, and IL-2, while Th2 cells produce IL-4, IL-5, IL-6, and IL-13 (144,147).
Another Th ceil type with a unique cytokine secretion pattern is the Th3 ceIl (146,1 52,153) which appears
to be a CD4 immune regulatory T celI that secretes TGF-3 (146). ThO ceNs have been described as
producing both IL-4 and IFN-y (141,144), but their actual existence is controversial.
Thl and Th2 ceNs have been associated with specific immune responses due to the cytokines
they secrete (Figure 10). For pathogens that require internalization, the presence of Thi cytokines (IFN-y
and TNF-3) is consideted necessary. Conversely, for large extracellular parasites such as helminths, Th2-
type cytokines (IL-4 and IL-5) have been consideted most protective (145,154,155,156). In the case of
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Thi-type cytokines, IFN-y has a multitude of functions. It promotes phagocytosis and upregulates
microbiai killing. In particular, it induces lgG28 (in mice) which s known to opsonize bactetia. On
phagocytes, IFN-y promotes the expression of FccRp receptors, which are used for phagocytosis. IFN-y
provides ail the tools necessary to eliminate most external microbes (155,156,157,158). For the classic
Th2 cytokines, IL-4 promotes production of neutralizing antibodies (lgG1) and the mast ceH/eosinophil
degranulating antibody IgE (157,158). IL-4 aiso promotes upregulation of IgE receptors on mast celis,
eosinophils and macrophages, and it induces membrane expression of MHC class II molecules and the
IL-4 receptor on macrophages (157). IL-4 and IFN-y often exist in an antagonistic relationship. IFN-y
blocks IgE and IgG1 production, while IL-4 blacks IgG2a secretion (1 58).
The majority of aliergen-specific T ceil clones derived from the peripherai blood of atopic
individuals produce increased amounts of IL-4 and IL-5 and lower levels of IFN-y (159). Coiiectively the
current biology of T cells in asthma suggest that they have the most important role in regulating ceilular
inflammation.
7.3.8 Leukotrienes
The cysteinyl leukotrienes (cys-LT) LTC4, LTD4, and LTE4, originally described as the slow
reacting substance of anaphylaxis (SRS-A), are proinflammatory mediators that play an integral raie in
the pathophysiology of asthma. Cys-LTs function as potent bronchoconstrictors and asthmatic patients
demonstrate increased production of cys-LT during naturaiiy occurring asthma and acute asthma attacks
as well as after allergen and exercise challenge (160).
Leukotrienes are eicosanoids that are produced de nova from the ceIl membrane phosphoiipid
arachidonic acid by the activity of 5-lipoxygenase in conjunction with 5-lipoxygenase-activating protein.
This reaction generates the unstable leukotriene A4, which is, in turn, converted either ta the chemotaxin
LTB4, or ta cysteinyl leukotrienes LTC4, LTD4, and LTE4 (161). In humans, the cysLTs are at least 100-
1000 times more potent bronchoconstrictors than histamine (162). They aiso increase airway blood flow
and vascular permeability, allowing the exudation of plasma macromolecules and contributing ta the
airway edema that characterizes asthma (163,164,165). In addition, the cys-LTs induce mucus secretion
(166) and reduce respiratory ciliary motility, hampering mucociliary clearance (167).
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LTD4 and LTE4 are potent and specific chemoattractants for eosinophils which are recognized as
the predominant celi type in asthma-reiated inflammation (168). A recent study has forged an important
link between cys-LTs and the variable eosinophii response to aliergen challenge (169). 0f 18 asthmatic
patients, 9 produced a significant (>200-folU) increase in cys-LT levels in the BAL 24 ht after inhaled
ailergen challenge, whiie the other 9 showed no significant increase (<20-fold). Oniy the high LT
producers showed a significant rise in BAL eosinophils atter allergen challenge, accompanied by
increases in LT84, IL-5, IL-6, and total protein. The “high LT producer” phenotype may thus be
synonymous with a subgroup of asthmatics with a high level of airway eosinophiiia. The celiular sources
of excess cys-LT production in the airway are unclear. Following inhaled allergen challenge, release of
LTC4 into BAL fluid is associated with simultaneous release of histamine, PGD2, and ttyptase, suggesting
a mast celi source for ail four mediators (170). However, in persistent asthma, the eosinophil itself may be
an important source of LTC4. In allergic and nonallergic asthmatics with mild, moderate and severe
disease, eosinophils represent the majority of bronchial mucosal ceils expressing LTC4 synthase, the
terminal enzymes in the LTC4 synthetic pathway, with only small numbers of mast celis and macrophages
expressing the enzyme. In mild allergic asthma patients with seasonal symptoms, the numbers of ceils
expressing LTC4 synthase rose 4 to 5 fold in the pollen season and the overwhelming majority of these
ceils are eosinophils (171). Taken together, the data suggestthatthe release of cys-LTs from eosinophils
themselves may sustain a seif-perpetuating cycle of eosinophil recruitment and futther cys-LT synthesis
in a significant subpopulation of asthmatics. A high capacity for cys-LT synthesis appears to be the
predisposing factor, possibly triggeted by cys-LTs released from allergen-activated mast ceils. Within the
airway, the capacity of rectuited eosinophils to generate cys-LT may be upregulated by Th2 type
cytokines (172) and also by contact with human bronchiai epithelial cells (173). Eosinophil-derived cys
LTs may be most important in chronic impairment of lung function, with mast cell-derived cys-LTs more
important in the acute response to allergen and other stimuli.
1.3.9 Cytokines
Inflammation of the airways underlies the pathology of tespitatory disorders such as asthma and
chronic obsttuctive pulmonary disease. No one mediatot of inflammation is responsible for ail the clinical
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and pathological changes of asthma (Figure 11). The primary inflammatory profile of asthma consists of
an accumution of CD4+ T helper type 2 (Th2) lymphocytes and eosinophils in the airway mucosa. Th2
cells orchestrate the asthmatic inflammation through the secretion of a series of cytokines, particularly IL-
4, IL-13, and IL-5.
1.3.9.1 Interleukin (IL)-4
IL-4 is a 20 kDa monomec secreted by Th2 celis, mast cells, basophils, and eosinophils. It was
originally identified as a B celI growth factor, which drives the optimal stimulation of B celis by antigen
(174). In addition, IL-4 stimulates B ceil expression of major histo-compatability complex (MHC) class II
molecules, b7-1 (CD86), CD4O, surface IgM, and the low affinity IgE receptor, resulting in enhanced
antigen presenting capacity of B cells (144). IL-4 also induces the immunoglobulin isotype switch from
IgM to IgE (175,176,177,178). Using in vitro priming models, t was shown that IL-4 is required for the
generation of IL-4 producing T cells (144). Another important activity of IL-4 in allergic inflammation is
inducing the expression of VCAM-1 on endothelial cells. This will produce enhanced adhesiveness of the
endothelium for T cells, eosinophils, basophils, and monocytes, which is characteristic of aflergic
reactions (179).
The raIe of IL-4 in IgE production can not be extended to inducing AHR, which is a major
characteristic of asthma. Overexpression of IL-4 in lungs ieads to a Ïymphocytic and eosinophillic
inflammation, but without AHR (180). Moreover, mice deficient in B ceil antibody production can exhibit
the phenotype of the experimental asthma modet (181,182). Thus, an essential effector raie for IL-4 in
experimental asthma has been difficuit ta show. Although IL-4 appears to play an important tale in Th2
cell development and recruitment to the airways (183,184,185), t is now generaiiy accepted that IL-4
does not have a similar raie in the development of AHR, at Ieast in mouse models.
Nevectheless, it has been shown that IL-4 receptor (IL-4R) biocking antibodies inhibit ailergen
ïnduced AHR (186), which is in contrast with the Iack of effect of anti-IL-4 antibodies on AHR in the same
model. Similar observations were obtained with IL-4RŒ deficient mice (187), which turned out ta be more
resistant ta the development of asthma than IL-4 deficient mice, suggesting that another IL-4Ra
interacting cytokine plays an important cote in this mode!. The obvious candidate is IL-13, a cytokine
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closely related to IL-4, which binds to IL-4Rc and is also produced by Th2 cells from patients with asthma
(188). Overexptession of IL-13 in the iungs induces inflammation, mucus hypersecretion and subepithelial
fibrosis. In addition, intratracheal IL-13 administration can lead to airway hyperresponsivness,
eosinophilia, and increased igE production in a mouse model (189,190). The candidate mechanisms for
IL-13 effects include direct alterations in epitheliai ceils or smooth muscle functïon because IL-13
receptors have been detected recently on these celi types (191). Direct evidence for the role of IL-13 is
confirmed by the observation that blocking its activity by intratracheal administration of soluble IL-13
receptor (IL-13R) reduced AHR and mucus production in a mouse model cf asthma (189,190,192).
1.3.9.2 Interleukin (IL)-5
Several unes of evidence suggest that IL-5 is important in asthma. IL-5 is an important growth
factor for eosinophils (193) and is increased in the lungs of allergic and nonallergic asthmatics (194). IL-5
expression in the lungs and sputum of patients with allergic asthma increases 24 hours after antigen
challenge (195) and a clear correlation exists between IL-5 expression and the presence of eosinophils in
the airways of patients with asthma (196). Intra-tracheal administration of IL-5 to human asthmatics or to
sensitized animais with the characteristics of atopic asthmatics increases the airway response to antigen
(197,198).
IL-5 acts on B cells and eosinophils in the mouse and seems to be restricted to eosinophils in
humans (199). IL-5 is crucial in regulating the eosinophillic response both in vitro (200) and in vivo, as
seen during helminth infections (201). Transgenic mice in which IL-5 is constitutively expressed in ail T
cells show a profound and life long eosinophilia, with large numbers cf eosinophils in the blood, spleen,
and bone marrow (202). When the IL-5 gene is inactivated in sensitized mice challenged with an antigen
aerosol, lung eosinophilia is absent and very littie inflammation and lung damage is observed (114).
Similarly, anti-IL-5 antibodies decreases the eosinophil infiltration induced by OVA inhalation in the
trachea of sensitized mice (203). Whereas blocking IL-5 reduces eosinophil responses to allergen, this
strategy falis short cf inhibiting AHR, both in mouse experimental models (204) and in preliminary human
observations (205). Thus, airway eosinophilia is flot a requirement for allergen induced airway
responsiveness (206,207). Although blocking IL-5 might fail ta prevent the acute phase cf asthma, this
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approach couid be an efficient way ta intertere with long term airway remodeiling, a process in which
eosinoph ils are thought ta be crucial.
7.3.9.3 Interferon-y
1FN-y is a glycoprotein produced by T cells (CD4, CD8, ‘y) and NK ceils (208). It binds the 1FN-y
receptor f IFN1iR) as an antiparaHel dimer. Although the iFN-yRa subunit binds 1FN-y with high affinity, it
requires an additional iFN-yR3 subunit ta transduce intraceilular signais (209,210). The resuitant cascade
involving tyrosine phosphorylation of signai transducers and activators of transcription (STATs) activates
up to at least 20 identifiable 1FN-y respansive genes. Ta date, 12 of these are unique ta IFN-y. The
transcription af these genes determines the biologicai and biochemical effects of 1FN-y (211).
The abiiity of 1FN-y to activate macrophages is central ta its raie in ceIl-mediated immunity. IFN-y
enhances macrophage microbicidai actions thraugh the reguiation of genes coding for the enzymes 0f
nitric axide (NO) synthase and the NADPH oxidase system (212). in addition ta activating macrophages,
1FN-y has been shown ta recruit and activate inflammatary and Thi ceils. IFN-y can directiy induce Thi
celi proliferation and augment antigen presentatian and T ceii activating capacity of macrophages. it
achieves this functian by increasing the ceil surface expression af major histacampatability ciass ii (MHC
Ii) and B7 on macrophages (213). 1FN-y facilitates the recruitment of Iyrnphcytes and macrophages ta
infiammatory sites by inducing 1CAM expression on endathelial ceils and pramates furthur accumulation
by the induction of chemotactic factors such as 1FN-y inducible pratein 10 (iPi 0) and LTB4 (214,215).
iFN1’ promotes the differentiation of CD8 and CD4 T ceils into active cytataxic cells (216,217).
In addition, 1FN-y enhances cytotoxic T-cell recognition and destruction of infected ceils by increasing the
expression of surface MHC I. This cytatoxic respanse releases viable organisms either protected in the
cytosoiic compartments of celis or persisting in senescent phagocytes, exposing them ta a different
display of effector inflammatory celis.
A number af cytokines antagonize the effects of IFN-y. Since inflammation due ta Thl immune
responses is associated with tissue damage, during the course of pratective immunity against microbes
such as mycobacteria, the presence af a system ta counterbalance Thi respanses is essential ta prevent
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progressive tissue damage. This is particulariy important because once a Thi response begins, they tend
to become self-perpetuating. The Th2 response is important in the regulation of the Thi process. IL-4, the
signature Th2 cytokine, inhibits inflammatory functions of macrophages and Thi cells (218). IL-4 inhibits
macrophage secretion of the monokines IL-1 and IN F-a and suppresses cytokine production by Thi cefls
(218). It also stimulates macrophages to produce IL-i receptor antagonist (IL-ira), e naturally occurring
inhibitor of IL-i activity. Both IL-4 and IL-13 activate intraceflular STAT proteins (STAT6) (219). These
pathways appear to facilitate IL-4 inhibition of the transcriptional activation of IFN-y inducible proteins.
Furthermore, IL-4 inhibits the ability of IFN-y to augment microbicidal activities including superoxide
production. Thi responses often appear early while Th2 cells predominate Iatet in an immune response
that suggests that the in vitro observation of Th2 responses may occur in vivo to limit the consequences
of Th J -mediated protective imm unity.
The mechanism(s) by which IFN-y protects against allergen-induced AHR are unknown. It is
possible that the inhibitory effect of IFN-y on AHR may be mediated by its action in inhibiting eosinophil
recruitment. However, there is no significant increase in airway and BAL eosinophilia with anti-IFN-y
antibody treatment, despite a significant enhancement of AHR (220). The protective function of IFN-y
might be conducted by Thl T lymphocytes or CD8 T cells suppressing Th2 ceils, eosinophils and
neutrophils, and ultimately reducing the Th2-orchestrated airway inflammation and AHR.
1.3.9.4 Interleukin-2
IL-2 is pivotai for the generation and regulation of the immune response. In mice, IL-2 is regarded
as e defining Thi cytokine, whiie in humans, this distinction is Iess clear (221). tL-2, a glycoprotein with e
single molecular size of 15.5 kD, is e pleiotrophic cytokine produced principafly by activated T-heiper ceNs
(222). It primarily functions in an autocrine fashion to clonaily expand antigen-specific T celis and
generate memory phenotypes. The IL-2-secreting T helper cells expand eariy after antigenic stimulation
and the subsequent differentiation into Thi or Th2 cells occurs under the influence of other cytokines
(223). Unlike IFN-y production by CD4 celis, which requires IL-2 during both priming and expression
phases, IL-4 production requires IL-2 only during priming phase (223). IL-2 also acts as a paracrine factor
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influencing NK ceil, B ceIl, and phagocyte function (224,225,226). IL-2 augments microbicidai activity,
cytokine production, and celi surface expression of cytokine receptors (226).
IL-2 stimulates T celis to undergo celi cycle progression via interactions with its specific
membrane receptors (227). Resting T ceNs do not produce IL-2, nor are they capable of responding ta IL-
2 when it is added exogenously (228). It has been shown that signais sent out from the T cell antigen
receptor complex co-ordinate the transcriptional activation of bath the IL-2 gene and the genes encoding
IL-2 receptors (229). Activation of the T cell receptar renders the ceils “competent” ta receive the cell
cycle “progression” signaIs that are provided by IL-2. IL-2 promates a graduai and sustained increase in
ceIl size and prepare the cell metabaiically for DNA repiication. IL-2 is considered the authentic G1
progression factor for T cells (230).
The essential nature of IL-2 and IL-2 receptors for the generation of a normal immune response is
readily demonstrated by a deficiency in the system. For example, immunodeficient athymic mice Iack the
capacity ta produce IL-2 but can respond ta IL-2 when it is supplied exogenausly (231). Patients suffering
from acquired immunadeficiency syndrome have similar immune responses as these athymic mice,
namely these patients have a selective loss of helper T cells resulting in the inability ta produce IL-2 and
other lymphakines in response ta antigen challenge.
Stimulation of the immune response via the IL-2 receptar is under ciinical investigation as a
patential new form af immunotherapy far cancer (232). The exact mechanism responsibie far the
beneficial effects is unclear, but it could be explained either by the IL-2-directed clonai expansion af
tumour-reactive cells or by stimulation af naturai killer cells. Others have used IL-2 as an adjuvant far
stimulating the immune respanse ta vaccines (233).
1.3.10 Chemokines
Chemakines are smali secreted prateins, whose main function is ta cegulate ceil trafficking. They
are ciassified into four subciasses: CC, CXC, C, and CX3C chemakines, based an the location of the first
twa cysteine residues in their sequence. Ta date, 23 human CC chemokines, 14 human CXC, and ane
each of the C and CX3C chemakine subclasses have been described (234). The bialogicai effects af
chemakines are mediated by ceil surface receptars. Nine CC chemakine receptars, five CXC chemakine
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receptors, one CX3C chemokine receptor, and one C chemokine receptor have been characterized.
Interestingly, there is a certain degree of promiscuity in the chemokine superfamily, with many Iigands
binding different receptors and vice versa (234).
The identification of eotaxin as the first chemokine with the preferential ability to recruit
eosinophils has drawn much attention to this molecule (235). Eotaxin was first discovered in the BAL fluid
of guinea pigs after allergen challenge (236). Unlike other eosinophil chemotactic factors, eotaxin binds to
a single receptor, CCR3, which is highly expressed on eosinophils (237,238). In human asthma, eotaxin
is produced at high concentrations and localises in the airway epithelium (238). Several other chemokines
including RANTES, MCP-3, and MCP-4 can also recruit eosinophils, probably through the CCR3 receptor
(238).
In the lung, eotaxin is produced by many celi types. The pcimary source of eotaxin following
allergen exposure is thought to be epithelial ceNs (239), but eotaxin can be produced by a large number
of other cell types including lung fibroblasts, airway smooth muscle, endothelial cells, alveolar
macrophages, eosinophils themselves, and lymphocytes (234).
Eotaxin acts in the early stages following allergen exposure, in conjunction with IL-5 to co
ordinate the differentiation of myeloid progenitor ceNs in the bone marrow and induce the export of these
cells into the peripheral blood and subsequently recruited to local sites of inflammation (240). Eosinophil
degranulation can be elicited by eotaxin, which has been found to be able to induce respiratory burst and
actin polymerisation (240).
The eotaxin-CCR3 axis is also responsible for the recruitment of a subset of Th2 lymphocytes to
the allergic site. This has been demonstrated by the ability of a CCR3 antibody to isolate IL-4 and IL-5
producing cells from the peripheral blood of atopic patients and that antibody inhibition of eotaxin in a
mouse adoptive transfer model can block the recruitment of Th2 cells into the lung and inhibit eosinophilia
and allergen-induced bronchoconstriction (241,242,243). It has also been shown that human blood
basophils express high levels of the CCR3 receptor and in vitro will release inflammatory mediators such
as histamine and leukotrienes following stimulation with eotaxin.
One of the several possible explanations for the redundancy of chemokines, particularly for the
CCR3 receptor, is that they may be expressed in a temporal fashion. Studies on the kinetics of ceil
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recruitment and chemokine expression showed that eotaxin plays a major rote in the recruitment of
eosinophils during the early phase reaction at 6h, but that eotaxin-2 and MCP-4 are involved in the late
phase accumulation of eosinophils at 24h post-chaltenge (244). Moreover, recent data from mouse
studies have produced evidence that Th2 lymphocyte recruitment into the lung is at least partially
dependent on the involvement of eotaxin up to a 4 day time point, but that by day 7, monocyte-derived
chemokine (MDC) becomes predominant in regulating Th2 celi infiltration in an adoptive transfer model of
lung inflammation (243). Thus, the recruitment of inflammatory celis over the entire period of the course of
a disease state like allergic asthma will Iikely be dependent on the spatial and temporal regulation of
chemokine expression.
1.4 Asthma Therapy
1.4.1 Drugs
Management of asthma begins with educating the patient about the disease. It also includes
environmental control interventions and the management of complicating factors such as sinusitis and
gastroesophageal reflux. Recent advances in understanding asthma pathogenesis, including the rotes
that cytokines, leukotrienes, adhesion molecules, and transcription factors play in the recruitment and
infiltration of inflammatory cells have leU to promising therapies, potential or already in use. These include
new generation inhaled steroids, leukotriene blockers, and antibodies against IgE. New inhalation devices
are using dry-powder formulations and vehicles such as hydrofluoroalkanes to deliver the active drug.
Experimental therapies include cytokine antagonists, adhesionmolecule blockers, and transcription factor
inhibitors. Oligonucleotide therapy, DNA vaccination, and new phosphodiesterase and tryptase inhibitors
are also being tested. Much of the research has focused on airway remodelling, and so the outlook for not
only asthma management but even reversibility or a cure is becoming optimistic.
The current options for asthma drugs can be placed in 4 categories: bronchodilators, anti
inflammatory drugs (nonsteroidal and glucocorticosteroids), leukotriene modifiers, and phosphodiesterase
inhibitors.
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7.4.1.7 Bronchodilators
Short-acting bronchodilators such as f32-adrenergic agents salbutamol and penoterol and
pirbuterol are useful as rescue medication and for acute symptom relief but they tend to have increased
systemic side effects. A long-acting bronchodilator, salmeterol, combines the active site of salbutamol
with a highly lipophillic side chain that appears to attach to an exosite of the 32-receptor on bronchial
smooth muscle, holding the salmeterol molecule in place for an extended period 0f time. Salmeterol is a
highly selective 32-agonist. Combined with moderate or even 10w doses of inhaled corticosteroids, it
improves lung function in patients with asthma and increases the number of symptom-free days.
7.4.1.2 Anti-inflammatory drugs
In persistent asthma, anti-inflammatory medication is crucial. The cromones — cromolyn sodium
and nedocromil, are acceptable for milU disease. However, they are flot as effective as inhaled
glucocorticoids for controlling inflammation or preventing airway remodelling. For many years, the
treatment of asthma has depended heavily on the use of glucocorticoids. These agents were introduced
into clinical practice in the 1940’s and proved extremely effective in controlling asthma in most patients
with the condition (245). However, long-term use of oral steroids leads to significant and unacceptable
side effects, so oral corticosteroids (OCS) therapy is restricted to those whose disease cannot be treated
effectively by any other means. The introduction of inhaled corticosteroids (lCSs) in 1970 was a major
advance, allowing many patients with relatively mild asthma to receive regular inhaled steroid therapy
(246).
Until recently, metered-dose inhalers fMDI’s) were the only devices available to deliver inhaled
asthma drugs. These hand-held, pressurized, multiple-dose systems administer aerosolized particles
measuring one to seven microns. They have disadvantages, including difficulty of use, need for spacer
devices, and use of chlorofluorocarbons (CFCs), considered as the primary cause of ozone depletion, as
vehicles. The first CFC-free inhaler became available in 1995. Since then other types of inhalers have
been introduced including dry powder inhalers, and inhalers using hydrofluoroalkanes as vehicles
(permitting a reduced particle size, which in turn improves distal penetration). lnhaled glucocorticoids
include beclomethasone, triamcinolone, flunisolide, budenoside, and fluticasone. A preparation of
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beclomethasone with ozone-friendly hydrofluoroalkane propellant is now available. A combination of
fluticasone and salmeterol is available as well as a combination of budenoside with another long-acting
2-agonist formoterol. At Iow doses, inhaled glucocorticoids are considered highly effective and safe. At
higher doses, bone growth and metabolism may be affected and bone density reduced.
7.4.7.3 Leukotriene Modifiers
These agents are fairly new and controversies persist on precisely when to use them. Zafirlukast
and Montelukast are Cys-LT1 receptor antagonists. Zileuton is the only available inhibitor of leukotriene
synthesis, acting by inhibiting 5-lipoxygenase. Zafirlukast is approved for use in asthmatic chiidren at
Ieast seven years old and Montelukast for chiidren at least two years old. As a group, leukotriene
modifiers alleviate asthma symptoms, improve objective measures of airway function, and decrease the
need for concomitant P2 rescue medication and inhaled corticostecoids. Individually, Montelukast has
been shown to be effective in reversing exercise-induced bronchospasm. Leukotriene modifiers can be
beneficial given in concert with other agents (more in 1.4.2.1).
7.4.1.4 Phosphodiesterase Inhibitors
Theophyfline, a bronchodilator was employed for many decades as asthma therapy and may
have potential as an adjunctive agent or for severe asthma in patients flot optimized on high dose inhaled
glucocorticoids. The drug is known to inhibit several of the intracellular enzyme phosphodïesterases,
which protect signal pathways essential for -adrenergic cellular responses, but studies have also
demonstrated anti-inflammatory effects unrelated to phosphodiesterase inhibition.
7.4.1.5 Steroid-sparing strategies
Much effort has gone into the search for safet inhaled steroids since it has been shown that
inhaled beclomethasone is absorbed and has detectable systemic effects in terms of reductions in short
term linear growth rates (247), but at present it remains uncertain whether these effects have any long
term adverse consequences on final height or on any other aspect of heaith (248).
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Troleandomycin: A macrolide antibiotic that was formerly used quite widely in asthma
exacerbations. It also inhibits the hepatic metabolism of methyl prednisolone (249), and it seems Iikely
that the beneficial effects results from this mechanism.
Cyclosporin A (CyA): A fungal metabolite that has successfufly been used as an
immunosuppressant agent in the prevention of rejection after organ transplantation. The principal action
of CyA is to inhibit 1-celI activation and suppress the production of cytokines associated with activation.
CyA blocks the late asthmatic reaction and inhibits eosinophil-assocîated cytokines after allergen
challenge (250). However, given the potential severity of side effects, there s insufficient evidence of
benefit to recommend its use.
Gold: Gold can inhibit some of the processes implicated in asthma, including IgE dependant
histamine release and neutrophil chemotaxis. Although gold can reduce doses of oral corticosteroids,
there is evidence of side effects which precludes its use as a promising therapy.
1.4.2 Therapeutic guidelines
Expert panels have classified asthma as intermittent or persistent. Persistent disease is turther
classified as mild, moderate, or severe. Intermittent asthma can be managed with inhaled 32-agonists.
Exercise-induced intermittent asthma may be relieved by warm-up exercises and use of 32-agonists,
cromolyn sodium, or nedocromil taken prior to exertion. Recent reports suggest that for exercise-induced
asthma a formoterol inhaler or Montelukast may provide more sustained relief than short-acting
agonists (251).
Mild persistent asthma requires long-term control medication, usuafly meaning the initiation of
anti-inflammatory agents such as low-dose inhaled corticosteroids. Other alternatives include leukotriene
modifiers, cromolyn or nedocromil. Acute asthma symptoms can be managed with intermittent use of
inhaled 2-agonists or occasional bursts of oral glucocorticoids. For moderate persistent asthma,
management includes long-term control medications such as moderate-dose inhaled corticosteroids or a
combination of low-dose inhaled steroids with a Iong-acting bronchodilator such as salmeterol or
formoterol. Severe persistent asthma usually requires oral glucocorticosteroids. lt is important to use the
lowest possible dose, to administer the drug on alternate days, and to monitor closely for adverse effects
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including osteoporosis and cataracts. Leukotriene modifiers may have some steroid-sparing potential and
under adequate management and with adequate compliance, many patients may be weaned from oral
glucocorticoids.
7.4.2.1 Efficacy of Inhaled corticosteroids vs antileukotriene drugs
The cornerstone of asthma treatment is inhaled corticosteroids. Iheir efficacy is a result of their
potent and broad anti-inflammatory properties. Antileukotriene drugs provide an alternative and novel
apptoach to the treatment (252). Ihe novelty of these new compounds is that they are targeting cysteinyl
leukotrienes, a major player in the pathophysiology of asthma. The antileukotriene drugs are more
effective than placebo, but they are flot as effective as inhaled corticosteroids in improving lung function,
reducing 32-agonist use, and decreasing symptom-free days. In contrast, they may have similar beneficial
effects on reducing asthma exacerbations and decreasing peripheral blood eosinophil counts. For
patients with mild and moderate disease there are a number of circumstances that support using an
antileukotriene drug first, such as in cases of aspirin tolerance, predominantly exercise-induced
symptoms and problems with using an inhaler or the adverse effects of inhaled corticosteroids such as
dysphoria and thrush. In addition, it has been shown that inhaled corticostecoids are not effective in aIl
patients with asthma (253). Corticosteroids produce minimal suppression of leukotriene production, and in
some cases enhance production (254,255).
Currently, tour antileukotriene drugs are approved for use in one or more countries. They are the
leukotriene synthesis inhibitor zileuton and the cys LI1 receptor antagonists zafirlukast, montelukast, and
pranlukast. Although these drugs differ in several pharmacokinetic and pharmacodynamic properties, and
in other properties as weIl (e.g. adverse effects, drug interactions), they are aIl effective in treating
patients with asthma (256,257).
The first published study that directly compared an antileukotriene drug and an inhaled
corticosteroid was reported by Malmstrom and colleagues in 1999 (253). Ihis was a randomized, double
blind, placebo-controlled, parallel group design, 12-week trial comparing the oral leukotriene receptor
antagonist Montelukast (lOmg once daily at bedtime) with the inhaled corticosteroid beclomethasone
(200pg twice daily). Bath treatments produced clinically important beneficial effects, reduced periphecal
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blood eosinophils and did not cause rebound loss of asthma control when therapy was stopped. The key
differences were that beclomethasone produced a larger beneficial effect, while montelukast had a more
rapid onset of action. Overall, using the patient populations described in the studies (mostly patients with
mild to moderate asthma) inhaled corticosteroids are more effective in the clinical trial setting. They
produce a greater improvement in lung function, as measured by FEV1, and a similar or greater reduction
in daytime and night-time symptoms and 32-agonist use. However, these resuits do flot take into account
differences in adherence to prescribed therapies in the “real world” setting. Problems related to improper
use of inhaled corticosteroids, and the unwillingness of some individuals to take inhaled medications,
result in beneficial effects that are typically less than what one would expect based on the controlled
clinical trials. These issues appear to be less important with the orally administered anti-leukotriene
drugs.
On the basis of the available data, inhaled corticosteroids have the advantage over the
antileukotriene drugs as monotherapy for the treatment of mild to moderate asthma. However, in patients
with moderate to severe disease, treatment requires the use of more than one medication. The
overwhelming consensus is that inhaled corticosteroids should be one of the medications. Which drug to
add next is more controversial. One potential advantage of the anti-leukotriene drugs over the others is
their ability to reduce airway inflammation in addition to their beneficial effect on pulmonary physiology.
1.4.3 Alternative Therapies
7.4.3.7 Anti-IgE
Since its role in the pathogenesis of allergic disease is central, lgE is an attractive target for
therapy. The first specific, selective anti-lgE therapy developed for study of humans is a unique
humanized monoclonal anti-IgE antibody called rhuMAb-E25 (or omalizumab). Omalizumab inhibited both
early and late phase reactions (258,103). Asthma exacerbations were significantly less frequent in the
omalizumab group than in the placebo group. lnterestingly, even subjects receiving placebo experienced
some improvement, meaning that the difference from active treatment s difficult to demonstrate (259).
49
7.4.3.2 Anti-histamine
Most new antihistamines display additional antiallergic effects and can modulate some
inflammatory phenomena (i.e. expression of adhesion molecules on epithelial and endothelial cells,
recruitment 0f eosinophils and mononuclear cells at the site of disease) (260). Therapeutically, its use s
improbable because antiallergic effects are usually obtained in vitro at concentrations much higher (10-
1000 times) than in vivo. Therefore, antihistamines cannot be presently considered as an alternative to
any of the standard antiasthma drugs.
1.4.3.3 Cytokines
Strategic approaches for cytokine inhibition include the blocking of transcription factors that lead
to their expression, blockade after release, cytokine receptor antagonism, and the inhibition of signalling
pathways that are activated after cytokine-receptor binding. Results with a humanized anti-IL-5 antibody
have been disappointing (205). Although successful in markedly reducing circulating eosinophils and in
preventing eosinophil accumulation in the airways, it is unable to reduce airway reactivity to methacholine
challenge in patients with asthma. A soluble IL-4 receptor antagonist has shown clinical benefits for
patients with moderate asthma, who require dally inhaled corticosteroids (186). Agents that target IL-13
and TNF-cL cemain to be evaluated in asthmatic inflammation. The use of cytokines with anti-inflammatory
effects may also have therapeutic value. The evaluation of such agents in human beings, including IL-10,
IL-12, and IFN-y, is at a preliminary stage, but so far the results have not been encouraging.
1.4.3.4 !mmunotherapy
Vaccination with allergen extracts are being considered as sttategies foc asthma. Vaccination with
mycobacteria has antiallergic properties. In Japan, early vaccination with BCG is associated with a
substantial reduction in the risk of developing allergy (261) although similar associations were flot
observed in studies performed in Sweden (262).
Two new approaches using DNA vaccines are undergoing serious consideration. The first
involves the use of CpG oligodeoxynucleotides (ODNs). Preadministration of CpG ODNs prevented both
airway eosinophilia and bronchial hyperresponsiveness in a mouse model of asthma (263).
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An alternative approach is to use allergen-specific naked DNA sequences as vaccines.
Preliminary data suggest that giving naked DNA leads to production of allergens from within the airways’
epithelial cells. Because of the different handling pathways for endogenous and exogenous allergens
(262), it seems that the endogenously produced allergen elicits a Thi-type response which in theory can
overcome the existing Th2 pattern response in human asthmatics and eliminate the allergy.
1.5 AnimaI Models
Animal models, including guinea pigs, monkeys, rats and mice, have been used to study the
pathogenesis of asthma. Rat and mouse models of allergic lung disease have been utilized to dissect the
complex pathaphysiological mechanism underlying the asthma phenotype. A wealth of research activity
has shown that rats and mice can be induced to display a range of the pathophysiological features that
are hallmarks of the human disease. These animal models have been shown to develop inflammatory
infiltrates in the lungs, both in peribronchiolar tissues (as shown in lung sections) and in the airway lumen
(collected in BAL). Although eosinophils are generally the most prolific ceil type within these infiltrates,
lymphocytes are also present in significant numbers. Lung sections show that there is an increase in
mucus secretion from the bronchoepithelïal surface. Analysis of serum reveals that rats and mice show an
increase in both total and allergen-specific IgE, as well as increased IgG2atiters. This Th2-type profile is
reflected in the cytokines generated within the lungs namely IL-4 and IL-5 being present in significantly
greater quantities than IFN-y. Many investigations have also documented changes in lung function
following allergen provocation, using a variety of techniques. The variety of protocols that have been used
to induce pulmonary eosinophilia, AHR, and mucus hypersecretion s tremendous. The use of animal
models has enabled researchers to highlight specific pathways and to study the function of these
pathways in vivo.
7.5.1 Brown Norway Rat Mode! of Aliergic Asthma
Brown Norway (BN) rats are a well established model of allergic asthma. This model reflects
many features of human allergic asthma, including both early and late phase reactions (264), elevated
antigen-specific IgE (265), airway inflammation (266), and increased airway responsiveness ta several
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stimuli (267). Allergen exposure of sensitized animaIs induces airway accumulation 0f inflammatory cells,
such as eosinophils, lymphocytes, neutrophils in BAL fluid, eosinophils, CD2, CD4, CD84 T cells in the
airway submucosa and expression of mRNA for Th2 cytokines. The BN rat is known to produce IgE in
large quantities after sensitization (268,269). Injecting BN rats with gold salts causes an important
increase in serum IgE concentration and this technique is used to identify the genetic determinants
controlling the IgE response (270). Mas et al. showed that rat chromosome 9, together with a region on
rat chromosome 10, plays a major role in the control of the IgE response (271). Sensitization of the BN rat
can be performed using a vaciety of antigens; the most popular of which are ovalbumin and house dust
mite injected subcutaneously. The sensitization procedure does not change the cellular profile of BAL
fluid, but even affer a single exposure to aerosolised antigen foliowing sensitization, airway inflammation
develops. After repeated exposure to antigen, BAL fluid contains an incteased percent of neutrophils,
eosinophils, and lymphocytes. This pattern is similar ta the cellular distribution of BAL fluid recovered from
asthmatic subjects after a local aliergen challenge (272). Neutrophil infiltration in humans is commonly
found in cases of severe asthma or status asthmaticus, while in the BN rat model, neutrophil influx ta the
BAL induced by allergen is usually prominent early on (273,274,275,276).
lncreased numbers of CD4 and activated IL-2 receptor-positive T cells can be observed in the
BAL and lung parenchyma, demonstrating that activated T helper cells are involved in the allergic
response in the lung of the BN rat asthma model (277,278). This observation is similar to the findings in
human asthma (277,278). Stimulation of similar amounts of CD4 or CD8 T cells revealed that both T cell
populations of BN rats produce significantly less Th1 and more Th2 cytokines than their Lewis rat strain
counterpart (279). The former group also showed that the BN rat CD8 T celI compartment produces only
one-quarter the amount of IFN-y produced by the CD4 T cell compartment, suggesting that the defective
IFN-y production by the BN rat CD8 T celi compartment may account for the susceptibility of this rat
strain to develop Th2-type immune responses. In another study comparing rat strains, Sirois et al.
showed that alveolar macrophages (AM) from BN and Sprague-Dawley (SD) rats are functionally different
(280). LPS and 0X8-stimulated AM from BN rats produce more Th2-type cytokines (IL-10, IL-13) than AM
from SD rats, suggesting that these celis may play an important raie in creating a cytokine milieu that may
favour the development of allergic reactions.
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The link between airway inflammation and airway responsiveness in BN rats has flot been ciearly
established. It could be that the inflammation aiters the mucoepithelial barrier, thus selectively increasing
the airway responsiveness to inhaled broncho-constrictor agents. BN rats develop a transient episode of
AHR within 24hr of an ovalbumin challenge which is associated with an increased number of eosinophils
and activated T lymphocytes bearing the CD25 marker in the BAL (273,281). Moreover, the cell influx and
AHR are abolished by corticosteroids (276). No clear relationship between eosinophilia and AHR has
been demonstrated in studies using the BN rat. For example, inhibition of allergen-induced eosinophilia
with the immunosuppressant cyciosporin A is not accompanied by a reduction in AHR (270), while
inhibition 0f AHR has been observed in the absence of any reduction in airway eosinophilia following anti
ICAM-lantibody treatment (282). lntravenousiy administered ovalbumin in the antigen-sensitized BN rat
causes bronchospasm (283) and microvascular leakage into the airways (284). Nagase et al have
demonstrated a role for 5-HT and leukotriene D4 in the increase in tissue resistance seen in the airways
after antigen administration in sensitized BN rats (283). BN rats antigen-induced bronchospasm appears
to be mediated equally by the activation of 5-HT and Cys-LT1 receptors with little or no involvement of
histamine or its receptors.
Recentiy, inconsistencies in eliciting a LR after ovalbumin challenge in the highly inbred BN rat
animal model prompted Turner et al (284) to study the airway responsiveness to aflergen in BN rats from
2 different continents. This study concluded that the same substrain of BN rat, namely SSN, showed
different responses to aliergen. Specifically, BN (SSN) rats from the United Kingdom (UK) produced
greater altergen-induced LR and associated cellular influx into the BAL than USA BN SSN rats. Moreover,
Th2 cytokines were expressed more in UK BN rats than in USA BN rats while the latter expressed more
Th1 cytokine in the lung tissue. We chose to use the USA BN (SSN strain) rats in our studies despite
these differences and re-estabiish a strong asthma phenotype, including eosinophilia, AHR, and a LR by
giving these animais IL-2 injections (11).
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1.6. Active Immunization Models
1.6.1. Sensitization and Challenge
This protocol relies on the delivery of an antigen to replicate a sensitization and challenge phase,
in order to mimic the allergic tesponse to exogenous or innocuous stimuli. This protocol involves
preimmunization with the allergen before a challenge phase in which the allergen is introduced to the
target organ, in the case of the lungs, either intranasally, as an aerosol, or via the trachea (286). This
basic protocol induces a pulmonary eosinophilia generally in conjunction with an increase in circulating
IgE levels. There are countless variations to this protocol including subtle differences in the route of
administration and the use of a variety of antigens, from complex microorganisms to simple proteins and
chemicals (287). Soluble protein antigens are widely used to elicit alletgic pulmonary inflammation and
range from simple proteins such as ovalbumin (OA) to complex, environmentally relevant antigens, such
as cockroach or house dust mite proteins (287). The most used protein is chicken egg QA, the use of
which models late-phase events such as eosinophilia, and in some protocols, AHR in vivo. OA is an
important human allergen and has the advantage of reliably inducing in rats and mice antigen-specific lgE
cesponses that are largely dependant on IL-4. Zhang and colleagues (1997) (288) found that a
combination of systemic and local exposure to QA resulted in a maximal and reproducible induction of
responses. These responses included AHR in vivo, production of allergen-specific IgE, peri-airway and
bronchoalveolar infiltration of eosinophils and increased expression of Th2 cytokines in the local Iymphoid
tissues.
1.6.2 Adjuvant
The use of adjuvant during the priming phase is to boost the immune response to the allergen in
use. Specifically, the use of aluminium compounds (alum) is associated with the induction of Th2
responses (289, 290). ONalum was found to induce IL-4 and IL-5 production in the absence of IL-4
signalling in IL-4R and Stat6 deficient mice (291).
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1.6.3 Dose
Constant and Bottomly (1997) concluded that there is no clear-cut conclusion regarding dose and
a corresponding development of specific immunity but pointed out that the type o! antigen used is critical
(292). They remarked that studies in which low dose Ihi-type responses were elicited used parasite
antigens, whereas 10w doses of soluble proteins tended to elicit a Th2-type response.
Antigen dose is an important issue in the context of immunotherapy. lmmunotherapy with
suboptimal doses of OA has been found to down-regulate AHR and BAL eosinophilia with e concomitant
decreased production of Th2 cytokines (293). However, the same study found that immunotherapy with
an immunodominant epitope of OA aggravates AHR and increases BAL eosinophilia (293).
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Avant-Propos
Much of the research in asthma has focused on the multiple proinflammatory mechanisms
involved in thïs complex inflammatary disease (3). The therapeutic approach ta this disorder has focused
on symptamatic contrai thraugh the alleviation 0f bronchospasm and the elimination of inflammation. The
direct relation of airway inflammation ta airway remodeiling and disturbances af lung function,
deveiopment of irreversible changes in lung function, and increased branchial responsiveness is complex
and difficuit ta assess. This thesis focuses on twa important components of airway inflammation:
cysteinyl-leukotrienes and interleukin-5, and their roles in the asthma phenotype.
The most widely studied biological effects of the cysteinyl leukotrienes are smooth muscle
contraction and vascular leakage. There is much less convincing evidence that the cysteinyl leukatrienes
cause any effects on ceIl-mediated inflammation. We decided ta use the Brown Norway rat model ta
investigate haw cysteinyl leukotrienes influences airway inflammation in asthma. This animal model has
been used extensively in the study of asthma because af its abiiity ta mount a high IgE response, a
cammon indicator of asthma, fallowing antigenic stimuli. Howevet, these animais are unabie ta mount a
physiolagicai response ta antigen. A recent study by Renzi et al showed that by giving these animais IL-2,
they were able ta have an increased airway response ta antigen (10). Therefore, ta study how
leukotrienes affect the physiologicai and inflammatory response in BN rats, we first promoted the animais’
celI-mediated immunity with IL-2 and then gave the animais Montelukast, a cysteinyl leukatriene receptar
antagonist to inhibit leukotriene activity. We measured the physiological and inflammatory response with
the following tests: airway responsiveness ta leukotrienes, the late airway response foilowing antigen
challenge and airway inflammation, namely celi influx and cytokine production. These tests allawed us ta
characterize the physiologic effects of leukotrienes in a pseudo asthmatic airway and the changes in the
cellular and cytokine profile in the lung.
Having measured cytokine expression in the lung, we decided ta furthur study specific changes
that cytokines, specificaiiy IL-5, can cause in the airways. In order ta study these changes, we agaîn used
the Brown Narway rat model, as aur experimental system because it represents an animai madei nat
predispased ta maunt a physiolagic or a complete immunalagicai response fie. Eosinophils, Th2
cytokines) following antigenic stimuli. Therefore by challenging these animais with IL-5, we would observe
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functional and cellular changes caused directiy by IL-5. The ultimate question being answered is can IL-5
alone convert normal rats into rats with an ailergic phenotype? Once the animais were challenged with IL-
5, we measured airway responsiveness to methacholine, the eariy and late airway response to antigen,
lung resistance, and airway inflammation.
These experiments increase in recognition and understanding of asthma as an immune-mediated
disease. Because airway inflammation, such as leukotrienes and IL-5, has profound effects on the
immune system, they influence both the pathogenesis of asthma and its ongoing status. This study
concludes that there is indeed a direct relationship between cysteinyi Ieukotrienes and the airway
response and ceII—mediated immunity, however one such mediator, IL-5, is unabie to cause a compiete
asthmatic phenotype.
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Materials and Methods
2.1. Cysteinyl Leukotrienes, Cellular Immunity and the Airway Response to antigen of BN rats
2.1.1 Animais and sensitization
Sixty-two highly inbred male BN SSN rats, 7-8 weeks old and weighing 200 to 240g were
obtained from Harlan Sprague-Dawley Inc. (Walkerville, MD). Rats were maintained in conventional
animal facilities at the Research Centre of Notre-Dame Hospital, Montreal. The Animal Care Committee
approved ail the experiments that were performed in this study.
Rats were sensitized on day 1 by subcutaneous injection of 1 ml of saline containing 1 mg of OA
and 200 mg of aluminium hydroxide (Sigma Chemicals, St. Louis, Ml).
2.1.2 Measurement 0f lung resistance
Rats were anaesthetised with either somnotol (50 mg/kg i.p.) [LTD4 responsivenessJ or urethane
(lg/kg i.p.) [ERILR]. A heating pad was used to maintaïn body temperature constant during the
experiment and rectal temperature was monitored continuously with an electronic thermometer. Lung
resistance (RL) was measured during spontaneous tidal breathing with the animais in the supine position
as previously described (11). Flow was measured by placing the tip of the tracheal tube inside a small
Plexiglas box (265 ml in volume). A Fleisch no.O pneumotachograph coupled to a piezoresistive
diffecential pressure transducer (Micro-Switch 163PC01D36, Honeywell, Scarborough, Ont. Canada) was
attached to the other end of the box to measure airflow. Transpulmonary pressure (Ptp) was measured
using a water-filled catheter placed in the lower third of the esophagus connected to one port of a
differential pressure transducer (Transpac Il, Abbott, Illinois); the other port was connected to the
Plexiglas box. The esophageal catheter consists of a polyethylene tube (PE-240, 6 cm. long).
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The pressure and flow signais were amplified, passed through eight-pole Bessel filters (modei
9O2LPF, Frequency Devices, Haverhill, MA) with their cut off frequencies set at 100 Hz. The data was
recorded and stored on a computer. The arway response was evaluated from RL, which was determined
by fitting the equation of motion of the lung by multiple linear regression using commercial software (RHT
lnfodat Inc, Montreal, Quebec, Canada). Endotracheal tube resistance was 0.11 cm H20/mIls at a flow of
25 mI/s. Tube resistance was subtracted from ail values of Rc.
2.7.3 Experimental Protocol
2.7.3.7 Experiments assessing the ainNay responsiveness to LTD4
Our study investigated the effects of lung agonists, such as LTD4, in an animal model at a state of
heightened cell-mediated immunity; a state commonly found in asthmatics. Therefore, we chose to inject
IL-2, a known T-cell growth factor, into rats to boost their ceilular immunity. Twenty-two rats were given
either 0.2 ml 0f saline or 20,000 units of human recombinant IL-2 diluted in 0.2 ml of saline
subcutaneously twice a day for 4.5 days from the 9th to the 14th day after sensitization. On day 14, rats
were challenged with incremental doses of LTD4 (0.05 ng/mI to 1 000ng/ml) (Cayman Chemical Company,
Ann Arbor, Michigan) intratrachealiy in 5Opl until a doubling in lung resistance occurred (Figure 12). LTD4
was given to rats intratracheally at doses established in previous studies (294).
2.7.3.2 Experiments assessing the effects of montelukast on IL-2 induced increased ainway
responsiveness after OA challenge
Four groups of rats were studied (Figure 13). The first 2 control groups consisted of twenty
sensitized rats that were given 0.2 ml of saline subcutaneously twice a day for 4.5 days, from day 9 to day
14 after sensitization, and were challenged with an aerosol of saline or OA on day 14. The second 2
experimental groups consisted of twenty sensitized rats that received 20,000 units of human recombinant
IL-2 subcutaneousiy twice a day for 4.5 days from the 9th to the 14111 day affer sensitization. On day 14,
prior to and 2 hours following OA challenge, rats received an i.v. injection of 0.36 ml of saline or
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montelukast (MK-0476, 0.5mglkg, Merck Frosst, Montreal, Quebec). MK-0476 was flot tested atone for
two reasons. One, the objective of this experimental protocol was limited to studying the IL-2-mediated
lung response in BN rats. BN rats flot treated with IL-2 do not mount an airway response, therefore giving
MK-0476 to these rats could flot be justified. Moreover, MK-0476, an experimental drug at the time, was
graciously donated by Merck Frosst and in a quantity sufficient to test only the principal questions of our
study. Alt rats were challenged with an aerosol of saline or OA (lmg/ml) for 5 minutes. Lung resistance
(RL) was measured at baseline, 5, 10, 15, 20 and 30 minutes after challenge and subsequently every 15
minutes for a period of 8 hours.
2.7.4 Bronchoalveolar Lavage (BAL)
Eight hours after OA challenge, the lungs wete lavaged through the tracheal tube by five
instillations and immediate retrieval of 5ml of saline at room temperature. The ceils were separated from
the supernatant by centrifugation, washed and the total celi count was determined with a hemacytometer
as previously described (10). The differential count was assessed on a cytospin slide that was prepared
with a Cytospin model III (Shandon, Pittsburgh, PA) and stained with Wright-Giemsa (Biochemical
Sciences, Swedesboro, NJ). At least two hundred oeils were counted under oit-immersion microscopy.
2.7.5 Lung Retrieval and Preparation
After performing BAL, the chest wall was opened and animaIs were exsanguinated by cardiac
puncture. The pulmonary vasculature was washed by slowly injecting balanced saIt solution (lOmi) into
the right ventricie until the lungs were white. The right lung was fixed in fresh 4% paraformaldehyde for in
situ hybridization, while the right lung was snap frozen in liquid nitrogen for semi-quantitative polymerase
chain reaction (SQ-PCR).
2.7.6 RNA preparation, reverse transcription and PCR
TRIzol reagent (Gibco BRL, Montreal, Quebec, Canada) was used as a monophasic solution to
homogenize tissue and to isolate total RNA from frozen biopsies according to the manufacturer’s
instructions. Reverse transcription was performed on 5 pg of total RNA with Moloney murine ieukemia
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virus (M-MLV) reverse trancriptase (Gibco BRL, Montreal, Quebec, Canada) in the presence of RNasine
(Pharmacia, Montreal, Quebec, Canada). PCR was performed by using an automatic thermal cycler (MJ
Research Inc., Ottawa, ON, Canada). Cycle conditions were 94°C for 1 mm, 60°C for 2 mm, 72°C for 3
min. cDNA (2p1) was amplified in a 25-pI reaction volume containing 0.5 pM (each) dNTPs, 0.5 pM
primers, lU Taq Polymerase (Gibco BRL, Montreal, Quebec, Canada).
2.7.7 Semi-Quantitative Reverse Transcription Polymerase Chain Reaction
For semi-quantitative experiments, the PCR was set up as described above, except that the
reaction mixture contained 5 pCi/ml of [a32PJUATP as a tracer. Specific primers were used to amplify
selected cytokine messages (295). Preliminary experiments determined the optimal number of cycles for
each primer, which were as follows: cyclophillin (a housekeeping gene): 19 cycles, and IL-4, IL-5, and
IFN-y: 30 cycles. The above cycle numbers were selected as midpomnts of their respective linear ranges
for amplification of cDNA (2pl), and there was a linear correlation between input cDNA and the yield 0f
PCR products. Quantities of cDNA were standardized to yield equivalent amounts of PCR products for
cyclophillin and compared with each other. In order to determine the relative mRNA expression of each
cytokine present in different samples, 20 pI of the amplified product was electrophoresed through a
polyacrylamide gel, containing 5% urea, in Tris-acetate/EDTA(TAE) buffer. The gels were dried and
exposed overnight at -80°C using autoradiography film (Kodak, Rochester, MY). The radioactive signal
specific bands were quantified by an Instant Imager System 2000 (Alpha Innotech Corporation, CA). The
relative amount of radioactive signal (RS) of specific bands for each cytokine and cyclophillin were
calculated as follows: relative amount of cytokine mRNA = (RS for cytokine in sample)/(RS for cyclophillin
in sample).
2.7.8 In situ hybridization
In order to confirm the differences in Thl/Th2 cytokine expression obtained by SQ-PCR, we
performed in situ hybridization for IL-4 and IFN-y as previously described (295). Cryostat blocks wete
made from stored lungs and eight micron sections were cut consisting of an intact airway and surrounding
submucosa and placed on poly-L-lysine coated slides. Sections were incubated at 37°C for 12 hours and
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either processed immediately or stored at -80°C until used. The cDNA for IL-4 and IFN-y was subcloned
into the Bluescript RNA vectot (pBluescript SK, Stratagene, La Joua, CA) and sense and antisense
probes were generated by 17 and SP6 RNA polymerases. Labefling of RNA probes with digoxigenin
(DIG)-11-UTP was performed according to the manufacturer’s recommendations (Boehringer Mannheim,
Mannheim, Germany). The IabeHed probes were digested by aikaline hydrolysis to an average Iength of
100 to 200 bases before precipitation and hybridization was performed at 42°C for 12h. The slides were
washed in decreasing concentrations of SSC (4 X SSC to 0.1 X SSC) and RNase A (2Opg/mI) to remove
unhybridized probe. As a negative control, preparations were hybridized with DIG-UTP-labelled sense
probes under the same conditions. Specimens were then stained for 1 minute with Hoechst 33258 dye
(bisbenzimide; Sigma Chemical Co., St.Louis, MD.) at a dilution of I pglml in PBS for visualisation under
a Zeiss Axiophot fluorescence microscope (Cari Zeiss (Oberkochen), Ltd., Welwyn Garden City, UK).
Positive celis wete counted in a random coded order at x200 magnification. In the airway submucosa,
positive celis were counted along the entire length of the epithelial basement membrane in a minimum of
6 sections. Results are expressed as the mean number of positive cells per millimeter square of airway
basement membrane for each RNA probe.
2.1.9 Data Analysis (Section 2.7 to 2.7.8)
The concentration of LTD4 required to double RL (EC200RL) was obtained by linear interpolation
between the two concentrations bounding the point at which RL reached 200% of the control value.
Comparisons of airway responsiveness to LTD4 between groups were performed with 10g transformed
data and analyzed using unpaired, non-parametric Mann-Whitney tests. The LR was calculated as the
area under the curve of RL above the baseline value over the 3-8 hour period following challenge (9).
Data were analyzed using a Kruskal-Wallis nonparametric ANOVA test for groups of rats followed by
Dunn’s multiple comparisons test between twa independent groups of rats. Differences were considered
ta be statistically significant when p values were Iess than 0.05.
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2.2 Interleukin-5 and the Airway Response of BN rats
2.2.7 AnimaIs and sensitization
Ninety-three highly inbred male BN SSN rats, 7-8 weeks old and weighing 200 to 240 g were
obtained from Harian Sprague-Dawiey Inc. (WalkerviHe, MD). Rats were maintained in conventional
animal facilities at the Meakins-Christie Labs of McGill University or the CHUM Reseatch Centre. The
Animal Care Committees of each institution approved ail the experiments that were performed in this
study.
We actively sensitized the rats by subcutaneous injection of imI of saline containing 1 mg of
ovalbumin (OA) and 200 mg of aluminium hydroxide (Sigma Chemicals, St.Louis, Ml).
2.2.2 Eosinophll colony proliferation from peripheral blood mononuclear ceil progenitors (PBMNC)
These experiments were per[ormed to assess whether rhIL-5 induced eosinophil proliferation
from progenitors in rats as previously described in humans (296). We isolated PBMNC from ten BN rats
by centrifugation over Ficoll Hypaque. The cells were plated at a concentration of 1 x 1 û6 celis per ml in
35 x 10 mm tissue culture dishes (Falcon) in supplemented lscove’s-modified Dulbecco’s medium
containing 20% heat inactivated fetal bovine serum, 1% peniciilin, 1% streptomycin, 5 x 10 mol/L 2-
mercaptoethanol, 0.9% methylceiluiose with or without rhlL-5 (0.25, 1, 2 or 5 ng/mi). Mer 14 days of
culture at 37°C in a humidified atmosphere containing 5% CC2 in air, colonies (defïned as any
aggregation of more than 40 ceils) were counted by inverted microscopy and eosinophil-type colonies
fCFU-Eo) were counted as a function of their morphologic appearance. CFU-Eo appeared as tight,
compact aggregations of round, refractile cells and showed varying combinations of eosinophilic,
basophilic, and mixed eosinophilic-basophiiic celis on May-Grunwald-Giemsa staining.
2.2.3 IgE determination
Specific IgE levels to QA were determined by ELISA as previously described (297). Assays were
performed on 96-well microtiter plates (Immulon Il, Fisher, Pittsburgh, PA). Plates were coated overnight
65
with mouse monoclonal antibody to rat IgE (Zymed Labs Inc., San Francisco, CA) diluted 1:500 in
carbonate/bicarbonate buffer. Plates were blocked with PBS-0.5% Casein. A 1:10 dilution of serum in
PBS-0.5% Casein was prepared prior to addition of lOOpI to the plates. Biotin-labelled CA (0.02 mg/ml)
was added to the wells. The above steps were done at 2h intervals at 37CC. Between steps the wells
were washed three times with PBS-0.5% casein. Horseradish peroxidase conjugated avidin (Sigma
Chemicals, Montreal, Quebec) in PBS-0.5% casein (1:500 dilution) was added for 30 minutes. Plates
were developed at room temperature for 15 min. after addition of TMB substrate (Sigma Chemicals,
Montreal, Quebec) diluted (1:10) in substrate buffer, and were read with an ELISA plate reader (SLT Lab
Instruments, Fisher Scientific Go., Pittsburgh, PA) at 450nm.
2.2.4 Endotoxin determination and challenge
The concentration of endotoxin in the administered rhlL-5 was quantified using the Limulus
Amebocyte Lysate (LAL) test (Associates of Cape Cod, Falmouth, MA). The same concentration of
endotoxin (Lipopolysaccharide (LPS), Sigma, St.Louis, MC), diluted in 0.9% saline was given intra
tracheally to animaIs and airway responsiveness to Mch and inflammatory celis in the BAL were
measured.
2.2.5 Lung lavage (BAL)
These experiments were performed 14 days after sensitization. Forty-three rats were
anaesthetised with somnotol (50 mg/kg), intra-tracheally intubated and were awakened after intra
tracheal injection of BSA, rhIL-5 (1 to 10 pg) or 10 pg rhlL-5 and 50 ng TRFK5 (BD Biosciences, Canada).
Twenty hours later the animaIs were again anaesthetised with somnotol, intubated and BAL was
performed after methacholine (Mch) challenge. The BAL retrieval is described earlier in section 2.1.4.
2.2.5.7 Staining of BAL celis for major basic protein (MBP)
The cells obtained from BAL were fixed in acetone-methanol, washed in Tris-Borate solution
(TBS), incubated with blocking solution (Dako Diagnostics, Mississauga, Ontario) (10 minutes) and
incubated with 60,il of primary monoclonal MBP lgG antibody (diluted 1:30 in Tris Borate Solution (TBS))
at 4°C in a humid chamber overnight (11). The next day, slides were again washed with TBS, and
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incubated with secondary anti-primary antibody for 45 minutes at room temperature. The siides were
washed again in TBS, and incubated with Streptavidin-Aikaline phosphatase antibody (Dako Diagnostics,
Mississauga, Ontario) for 45 minutes at room temperature. Signais were reveaied using a Fast Red stain
(Sigma Chemicals, St.Louis, MD) and viewed under a Nikon Eclipse E600 microscope (Nikon, USA) at
40X magnification.
2.2.6 Measurement of lung mechanics
Lung mechanics measurements followed protocols detailed in section 2.1.2.
2.2.7 Airway responsiveness to methacholine
Fourteen days after sensitization, rats were given either rhIL-5 (1, 3 and lOpg), lOpg of rhIL-5
and 50 ng TRFK5 or 60 Endotoxin Units (EU) of LPS (Figure 14). The latter two groups underwent airway
responsiveness to methacholine tests only 20 hours later. The dose of rhIL-5 was based upon previous
studies involving guinea pigs (298) and humans (299). 10 ug 0f rhIL-5 given nebulized to asthmatics was
shown to be sufficient to increase airway responsiveness and infiltration of eosinophils into the airways.
30 minutes, 20 hours or 72 hours later rats were anaesthetised with somnotol (50 mg/kg), intubated and
baseline RL was measured. Rats receiving lOpg of IL-5 was also challenged with a nebulized aerosol cf
OA (50 mg/mI in sterile water) for 30 seconds 20 hours after IL-5 administration. Ail rats were given an
aerosol of phosphate-buffered saline (PBS) followed by progressively doubling concentrations of Mch
(from 0.0625 to 32 mg/ml in sterile saline) and RL was measured after each aerosol until it increased to at
least 200% of the PBS baseline value. Aerosols were generated from 3m1 of solution using a Hudson
nebulizer with an airflow of 10 L/min; each administration lasted for 30 seconds.
2.2.8 Measurement of airway responses to OA
Fourteen days after sensitization, rats were anaesthetised with somnotol (50 mg/kg), intra
tracheally intubated and received either IL-5 (3pg) or the same weight of BSA intra-tracheally prior to
being awaken (Figure 14). This specific dose of IL-5 was given to animais based on a previous
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experiment by Lilly et aI (298) that showed that instilling 5ig of IL-5 to guinea pigs caused a peak in
airway eosinophilia. We chose 3tg as a comparable dose to a smaller mass animal model. The following
day, rats were anaesthetised with urethane (1.1 glkg), intubated and baseline RL was measured. The rats
were then challenged with aerosolized QA (50 mglml in sterile water) by using a Hudson nebulizer (Model
1400; Hudson, Temecula, CA) et airflow of 10 L/min for 5 minutes. RL was measured before and at 5, 10,
and 15 min after the OA challenge, and at 15 min intervals for a total period of 8h.
2.2.9 Lung mincing and digestion
These experiments were performed 8 hours after OA challenge as previously described (296) in
16 rats either pre-treated with 3 pg of IL-5 or 3 pg of BSA. The chest wall was opened, and the animal
was exsanguinated after puncture of the left ventricle by section of the abdominal aorte. Blood was kept
in a heparinized tube for analysis of lymphocyte subsets by fiow cytometry. The pulmonary vasculature
was washed by slowly injecting balanced saIt solution (IOmI) into the right ventricle until the lungs were
white. The lungs were dissected from the chest and mediastinal structures, weighed, and separated into
the large airways (trachea and large bronchi until approximately the fifth generation) and small airways
and parenchyme (SIP). Tissue digestion and cell retrieval through a #60 sLeve (Sigma) was performed
and slides were prepared by centrifuging 500,000 cells in enriched RPMI 1640 for 5 min et 400 rpm in a
cytocentrifuge. The cellular differential was assessed on a Wright-Giemsa stained slide by counting 200
cells undet oil-immersion microscopy.
2.2.10 Isolation and staining of blood lymphocyte subsets
Peripheral blood mononuclear cells were isolated from fresh heparinized peripheral blood by
standard Ficoil-Hypaque methods and prepared for flow cytometry as previously described (300). The
isolated cells were washed with Hanks balanced saIt solution and stained directly by incubating with the
monoclonal antibodies W3/25 (equivalent of the CD4 helper lymphocytes) or 0X8 (CD8
suppressor/cytotoxic lymphocytes) for 30 min. Cells were studied immediately or flxed in 1%
paraformaldehydelo.85% saline. The fixed cells were stored et 4°C in the dark until analysis. Flow
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cytometry was performed with an argon laser, 488nm FACScan analyzer (Becton Dickinson FACS
Division, Sunnyvale, CA) focusing on the lymphocyte cluster. Controls consisted of celis stained with
polyclonal antibodies obtained from mouse ascites fluid.
2.2.17 Measurement of cytokine mRNA expression
These experiments were performed 20 hours after OA challenge as previously described (298) in
16 rats either pre-treated with 3 pg IL-5 or BSA. Alt the animaIs were killed by exsanguination. The Iungs
were dissected from the chest atter perfusion of the pulmonary vessels, fixed in 4% paraformaldehyde
and then transferred an hour later into a 15% sucrose in PBS solution et 4°C. Airways from the lung were
cut transversely into 1cm pieces, and blocked with liquid nitrogen. Cryostat blocks were cut at a depth of
8 pm/ section, placed on poly-L-Iysine coated slides and stored at -80°C.
In situ hybridization was performed as previously described (301) and as detailed in section 2.1.8.
2.2.12 Statistical analysis (Section 2.2 to 2.2. 11)
The concentration of Mch required to double RL (EC200RL) was obtained by linear interpolation
between the two concentrations bounding the point at which RL reached 200% of the control value.
Comparisons of airway responsiveness to Mch between groups were performed with log-transformed
data. b compare the prevalence of ER among treatment groups, we defined e significant ER as an
increase in RL to at least 150% of the baseline value within 1 hour after OA challenge. The late response
was calculated as the area under the RL vs. time curie from 1 80-480 min post challenge. The differences
between the tested and control group means were analyzed using Student’s t test or the Mann-Whitney
U-test, as appropriate, to compare magnitude, time to peak, ER and LR, inflammatory cells and cytokines.
Resuits are presented as mean + SEM, except for values of EC200RL, which are reported as geometric
means. b determine the statistical significance of the airway responsiveness to Mch challenge, we
employed unpaired student’s t test. Significance was accepted when the probability (p) value was <0.05.
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2.2.73 Chemicals
Ovalbumin, BSA, APAAP, urethane, Mch, paraformaldehyde, coHagenase, and Wright-Giemsa
stain were purchased from Sigma Chemicals (St.Louis, MI); Bordetella pertussis vaccine was purchased
from the Armand Frappier Institute (Montreal, Quebec, Canada); Fetal caif serum, penicillin, streptomycin,
L-glutamine, nonessential amino acids, RPMI 1640 medium, Iscove’s modified Dulbecco’s medium,
HBSS and tryptan blue were obtained from GIBC0 Laboratories (Grand Island, NY). Ficoli-Hypaque was
obtained from Pharmacia (Montreal, Quebec, Canada). RhIL-5 was graciously donated by Merck Frosst
(Montreal, Quebec, Canada). Somnotol was used ta put rats ta sleep and was abtained from BDH
Pharmaceuticals (Mantreal, Quebec, Canada). Harris Haematoxylin was purchased fram Zymed
Chemicals (California, USA). W3/25 and 0X8 were abtained fram DAKO, Cedarlane (Carpinteria, CA).
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Resuits
Pre-treatment with IL-2 increases airway responsiveness to LTD4
b determine the relationship between LTs and upregulation of celI-mediated immunity, rats were
pre-treated with either saline or IL-2 for 4.5 days and after general anaesthesia and endotracheal
intubation were challenged on the 14th day after sensitization with exponentiafly increasing doses of LTD4
to measure airway responsiveness. Rats pre-treated with IL-2 showed increased airway responsiveness
to LTD4 (fig. 15). The mean dose of LTD4 that caused a doubling in resistance was 88.2 + 38.4 ng/ml
(n=10, 1 rat dieU during the procedure) for IL-2 treated rats. Rats pre-treated with saline required a higher
dose 0f LTD4 in order to double lung resistance (665.7 ± 47.6 nglml, n=1 1, p <0.05).
Montelukast, a cys-LTI receptor antagonist, inhîbits the IL-2-med,ated increase in LR after OA
challenge
Montelukast (MK-0476) was given i.v. in order to block the effects of LTs on the cys-LT1 receptor.
In animais given IL-2 and then challenged with QA, montelukast blocked the LR significantiy (n10, 1 rat
dieU during the procedure) when compared to IL-2 pre-treated animais that received saline i.v. instead of
montelukast and were then OA challenged (n10, 1 rat died during the procedure, LR: IL-2 + MK = 4.54 +
0.61 vs. IL-2 + Saline = 26.49 + 5.96, p<0.05) (fig. 16).
Effect of IL-2 and montelukast on the differential celI count in the BAL
The administration of IL-2 significantly increased the total number 0f celis recovered in Iung
lavage 8 hours after antigen challenge when compared to rats that received saline and were flot OA
challenged (IL-2 + OVA: 6.47 ± 1.78 x 106 cells/ml vs. SAL + SAL: 2.93 ÷ 0.77 x 106 cells/ml; p<0.05).
The number of eosinophils in the BAL were significantly increased in animais pre-treated with IL-2 and
QA challenged when compared to saline pre-treated and either saline or OA chailenged rats (p<0.05, fig.
17). The absolute numbers of eosinophils rather than the percentage of eosinophils per total celis
counted in each group is reported here. Although the volume 0f cells was equal in each group, the total
number of cells recovered was signiflcantly different. Therefore, it is statistically incompatible to compare
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percentages between groups with unequal population sizes. Rats that received IL-2 and montelukast and
were OA challenged showed a trend for a decrease in the number of total ceNs and eosinophils found in
the BAL compared to those that received just IL-2 and DA challenged but this difference was not
significant (p>O.05).
Effect of IL-2 and montelukast on cytokine mRNA production
SQ-PCR analysis of lung cytokine mRNA obtained 8 hours after OA challenge showed that IL-2
pre-treatment increased the expression of Th2 cytokine (IL-4 and IL-5) mRNA 8 hours after OA challenge
(fig.18a, 18b). IL-2 pre-treatment also decreased the expression of the Thi cytokine mRNA IFN-y after
OA challenge (fig. 18c). Montelukast inhibited the effect of IL-2 on lung cytokine mRNA expression and
caused a decrease in IL-4 and 5 and an increase in IFN-y mRNA 8 hours after OA challenge.
Results obtained by SQ-PCR for Thi (IFN-y) and Th2 (IL-4) cytokines were confirmed by in situ
hybridization (figure 19a and b). Analysis of lung cytokine mRNA obtained 8 hours atter QA challenge by
in situ hybridization showed that IL-2 pre-treatment increased the number of IL-4 mRNA positive cells
(19a) and decreased the number of IFN-y mRNA positive ceNs (fig. 19b) in the submucosa of the airways
when compared to control challenged rats (p<O.05). Montelukast inhibited the increase in cells expressing
IL-4 mRNA but also increased the number of ceNs expressing IFN-y mRNA in IL-2 pre-treated rats after
DA challenge.
Effect of rhIL-5 on eosinophil colony formation from proqenitors
To determine if rhIL-5 exhibits significant functional activity in BN rats, BN rat PBMNC’s were
incubated in 0, 0.25, 1, 2, and 5 ng/ml of rhIL-5 in enriched RPMI medium for 14 days. Concentrations of
IL-5 above 1 ng/ml caused a significant increase in eosinophil/basophil colonies when compared to
controls (p<0.O5) and the number of eosinophil/basophil colonies increased with the concentration of rhIL
5 (fig. 20).
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Effect of ovalbumin sensitization on OA-specific IgE levels from serum
To show that BN rats were properiy sensitized to OA, serum from two activeiy sensitized rats was
coliected 0, 1, 2, and 3 weeks following sensitization. OA-specific IgE levels were measured in duplicate
and showed an increase in OA-specific igE levels (fig. 21).
Effect of intra-tracheal administration of rhIL-5 on airway responsiveness to Mch
Bovine serum albumin, 1, 3 or J0ig of rhlL-5 were administered intra-tracheaily and airway
responsiveness to Mch was measured 20 hours Pater. The amount of Mch that caused a doubling in RL
decreased significantIy as doses of IL-5 increased from 1ug to 10ig (fig. 22). The airway response to
Mch was significantly increased in the rats that received 3 pg of IL-5 when compared to the group that
received BSA (p< 0.05). The airway response to Mch was aiso significantIy increased in the group that
received 10 ig of rhIL-5 when compared to the BSA group (lOp.ig IL-5: 1.3 + 0.4 mg/ml vs. BSA: 6.5 0.9
mg/mI; p<0.01) (fig. 22). 50jg of TRFK5 significantIy reduced the effect of lOpg of rhIL-5 on the airway
response to Mch (4.75 0.48 mg/mi; p<0.05). Experiments testing the effect of LPS at a concentration
equai to that measured in the rhlL-5 (60 EU) showed no significant difference in airway responsiveness to
Mch with control animais. Airway responsiveness to Mch 30 min. and 72 hours after administration of
lOpg of IL-5 was flot significantly affected (Fig. 23).
Effect of dose of intra-tracheal rhIL-5 on the cellular return from lung lavage
Intra-tracheai administration of rhIL-5 increased the celiular return from BAL 20 hours Pater. The
6 6total cellular return was for ltig: 6.65 + 2.08 x 10 cells, for 3ig: 9.75 ± 1.84 x 10 cells and for lOpg:
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13.1 3.07 x 10 cells (p<0.O5). 50 ng of TRFK5 given in combination with lOpg of rhIL-5 significantly
reduced the total cellular return from the BAL (3.28 + 0.53 x 106 cells; p<0.O5). The number of neutrophils
increased significantly in the rats that received lOpg 0f IL-5 when compared to the group that received no
IL-5 (10 pg IL-5: 8.01 ± 2.21 x 106 cells vs. no IL-5: 2.78 ± 0.73 x i6 celis; p<0.O5). The effect of IL-5 on
BAL neutrophils was significantiy reduced by TRFK5 (2.23 ± 0.42 x 106 cells; pcO.O5). No difference was
found in the total number of macrophages, lymphocytes, and basophils that were present in the BAL of
each group (Macrophages: lOpg IL-5: 4.53 ± 0.92 x i6 celis vs. Controls: 3.95 + 0.27 x 106 cells;
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Lymphocytes: lOpg IL-5: 0.252 ± 0.067 X 106 cells vs. Controls 0.154 0.09 x 106 ceHs; Basophils: lOpg
IL-5: 0.0655 + 0.0403 x i6 celis vs. Controls: 0.05 ± 0.03 x io6 cells). Also, rats given TRFK5 did flot
show a significant difference between controls or IL-5 alone. There was no difference n total eosinophils
between ail groups when evaluated by Wright Giemsa stain or with an anti-MBP stain (Eosinophils: lOpg
IL-5: 0.243 ± 0.0403 x i6 ceNs vs. Controls: 0.092 ± 0.07 x 10 ceNs vs 10 pg IL-5 and 50 ng TRFK5:
0.0689 ± 0.02 x 106 cells; p>0.O5).
Effect of rhlL-5 on the physiologïcal response after ovalbumïn challenge
Pre-treatment with 3pg of rhIL-5 did not affect the ER (Figure 24a) or LR (Figure 24b) but
significantIy increased RL 20 hours after challenge with OA (IL-5: 0.178 ± 0.046 cm H20/ml/s vs. Control:
0.094 + 0.057 cm H20/ml/s, p = 0.01, Figure 25). There was no significant difference in responsiveness
to Mch between the group that was saline-challenged and given IL-5 and the OA-chailenged groups that
wete given BSA oc IL-5 (EC200RL: IL-5 + Saline: 10.69 + 0.55 mg/ml vs. BSA + OA: 11.8 + 2.93 mg/ml vs.
IL-5 + OA: 17.95 + 3.48 mg/mI; p>0.05, Figure 26).
Effect of rhIL-5 on blood lymphocyte subsets 8 hours after ovalbumin challenge
When compared to controls, pre-treatment with rhIL-5 caused significant differences in blood
lymphocyte subsets 8 hours after QA challenge. We found a higher percentage of blood CD8 cells in IL-5
pre-treated and challenged rats (mean control: 20.6 ± 5.8 vs. challenged: 30.6 ± 3.7, p <0.05), while the
mean percentage of CD4 cells was lower (control mean: 43.0 ± 6.4 vs. challenged: 32.8 ± 5.2, p <0.05).
The CD4ICD8 ratio in the blood of IL-5 pre-treated and challenged rats was significantly lower when
compared to BSA pre-treated rats (IL-5: 1.18 ± 0.47 vs. BSA: 2.92 ± 0.57, p <0.05, Figure 27).
Effect of IL-5 on lung cytokine mRNA expression after ovalbumin challenge
More cells were expressing mRNA for IL-4 in the aicways of IL-5-pre-treated rats 8 hours after
antigen challenge (IL-5 pre-treated: 1 .92 ± 0.28 positive cells/0.45 mm2 basal membrane vs. BSA
Control: 0.33 + 0.04 positive cells/0.45 mm2 basal membrane, p<O.O5). Similar tesults wece found for
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celis expressing IL-5 (IL-5 pre-treated: 1.19 ± 0.08 positive cells/ 0.45 mm2 basal membrane vs. BSA
Control: 0.25 ± 0.09 positive cells/0.45 mm2 basal membrane, pc0.05). However, we found no difference
in interferon-y mRNA expressing cells between both groups (IL-5 pre-treated: 0.482 + 0.042 positive celis?
0.45 mm2 basal membrane vs. BSA Control: 0.394 + 0.086 positive cells/0.45 mm2 basal membrane,
p>0.05).
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Figure 15: Effect of IL-2 on airway responsiveness to LTD4
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Figure 15: Effect of IL-2 on airway responsiveness to LTD4. Rats (n=21) received
either saline or IL-2 s.c. (20,000 Units/twice a day far 4.5 days pre-LTD4 challenge)
and were then challenged with increasing doses cf LTD4 (0.05, 0.5, 5.0, 50, 500, 1000
- ‘ml) until baseline RL doubled. EC200RL was calculated as the amaunt
o LTD4 necessary to double RL. * p<0.05 between IL-2-treated and saline
treated contrai rats.
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( Figure 16: Effect of Montelukast on IL-2-induced Late Airway Response
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Figure 16: Effect of IL-2 alone or IL-2 and montelukast on the late airway response
to ovalbumin. DA-sensitized rats (n=35) were given either IL-2 (20,000 Units/twice a day)
or saline for 4.5 days starting on day 9. on the J4th day they received either
montelukast (0.5mg/kg) or saline intravenously prior to and 2 hours following OA challenge.
° was measured for 8 hours after DA challenge and the LR was calculated as the area
ider the curve for RL values obtained from 4 to 8 hours after DA challenge.
* p<0.05 between IL-2 treated animais that received saline i.v. and IL-2 treated animais
that received montelukast i.v. prior to and 2 hours following OA challenge
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Figure 17: Effect of IL-2 and Montelukast on BAL Inflammatory cells
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Figure 17: Effect of IL-2 pre-treatment or IL-2 and montelukast on BAL
inflammatory ceils after OA challenge. BAL (n=35) was recovered 8 hours
after OA or saline challenge for celI differential analysis. * p<O.05 between
)A-chaIlenged IL-2 pre-tteated rats and saline pre-treated and saline-challenged
rats
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Figure 18A: Effect of IL-2 and Montelukast on lung IL-4 mRNA expression
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Figure 18A: Eftect of IL-2 pre-treatment with or without montelukast on IL-4 total( N9g cytokine mRNA expression after OA challenge. Lungs (n=JO) were fixed in
iiquid nitrogen 8 hours after challenge for SQ-PCR analysis.
*p.<005 between IL-2 pre-treated rats that received either saline or montelukast
i.v. prior to and 2 hours following OA challenge.
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Figure 18B: Effect of IL-2 and Montelukast on lung IL-5 mRNA expression
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Figure I 8B: Effect of IL-2 pre-treatment with or without montelukast on IL-5 total
,- ‘ing cytokine mRNA expression after OA challenge. Lungs (n=I0) were fixed inquid nitrogen 8 hours after challenge for SQ-PCR analysis.
*p<oo5 between IL-2 pre-treated rats that received either saline or montelukasti.v. prior to and 2 hours following OA challenge.
*
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Figure 18C: Effect of IL-2 and Montelukast on lung IFN-y mRNA expression
40000
35000
30000
25000
20000
15000
10000
5000
O
Saline + OA MK-0476 + OA Saline + Saline
Groups of EN rats
Figure 180: Effect cf IL-2 pre-treatment with or without montelukast on IFN-y totallung cytokine mRNA expression after OA challenge. Lungs (n=1O) were fixed in( iquid nitrogen 8 heurs after challenge for SQ-PCR analysis.
*p<005 between IL-2 pre-treated rats that received either saline or montelukast
Lv. prior to and 2 heurs following OA challenge.
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Figure 19A: Effect of IL-2 and Montelukast on IL-4 mRNA positive
ceils in the airways
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Figure 19A: Effect of IL-2 pre-treatment with or without montelukast on IL-4 mRNApositive ceils after OA challenge. Lungs (n=16) were recovered in PBS-Sucrosehours after OA challenge for in situ hybridization.
t 0.05 between IL-2 pre-treated rats that received either saline i.v. or montelukasti.v. prior ta and 2 hours following OA challenge
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Figure 19B: Effect of IL-2 and Montelukast on IFN-y mRNA positive
celis in the airways
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Figure 19B: Effect cf IL-2 pre-treatment with or without montelukast on IFN-y mRNA
positive celis after QA challenge. Lungs (n16) were recovered in PBS-Sucrose
8 hours after OA challenge for in situ hybridization.
6*p<OO5 between IL-2 pre-treated rats that received either saline Lv. or montelukast
i.v. prior to and 2 hours following OA challenge
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Figure 20: Effect of rhlL-5 on eosinophil progenitor colony formation
from rat peripheral blood mononuclear ceils
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Figure 20: Effect of rhIL-5 on eosinophil/basophil type colony production in rat
PBMNC’s (n=10). Ceils were cultured in medium alone or in different concentrations( f rhlL-5 for 14 days at 37°C and colonies were counted by inverted microscopy after
May-Grunwald-Giemsa staining. *p<005 between IL-5 groups (1,2 and 5ng/ml)
and control
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Figure 21: Effect of ovalbumin sensitization on OA-specific serum IgE levels
2-
o
Li’)
I.
2
w
o
1-
-o
k.
o
U)
-o
o- iiII -—- II
_
_
_
_
Week 0 1 2 3 Week 0 1 2 3
Rati Rat2
Figure 21: Effect of ovalbumin sensitization on OA-specïfic IgE levels. Serum was
collected in duplicate from 2 actively sensitized rats from week O to week 3 following
nsitization. OA-specific IgE levels was measuted using ELISA. Both animais showed
u major increase in OA-specific IgE levels from week O to week 3
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Figure 22: Effect of IL-5 on airway responsiveness to Methacholine
20 hours after administration
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Figure 22: Effect cf IL-5 on airway responsiveness te Mch 20 hours after
administration. Rats (n=26) received either lpg, 3pg, lOpg cf IL-5 or BSA(control) intra-tracheally followed by Mch challenge 20 hours later. 6 rats
were given 50 ng cf anti IL-5 antibody intra-tracheally immediately after
receivîng lOpg cf IL-5. 5 rats were given 60 EU of LPS 20 heurs priorto
Mch challenges. Doubling doses of nebulized Mch was given untiil baseline
RL doubled. EC200RL was calculated as the amount cf Mch necessary to
double RL. Bars represent the means cf each group. *p<0 05 between IL-5
treated (3pg) and BSA-treated (control). ** p<0.Ol between IL-5 treated (lOpg)
and BSA-treated (control). p<0.05 between IL-5 treated (lOpg) and lOpg IL-5
with 5Ong TRFK5.
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Figure 23: Effect of lOpg rhlL-5 on airway responsiveness to Methacholine30 minutes and 72 hours after administration
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Figure 23: Effect of lOpg of IL-5 on airway responsiveness to Mch 30 min. and 72hours after administration (n22). Rats received either lOpg of rhlL-5 or BSA(control) intra-tracheally followed by Mch challenge 30 min. or 72 hours later
Doubling doses of nebulized Mch was given until baseline RL doubled. EC200RL
s calculated as the amount of Mch necessary to double RL. Bars represent the
mean of each group
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Figure 24A: Effect of pre-treatment with rhlL-5 on Early Airway Response
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Figure 24A: Effect of pre-treatment with rhlL-5 on the ER after antigen challenge.
Rats (n=23) were sensitized to OA and received either 3pg of rhlL-5 or BSA
intra-tracheally. Twenty hours later, rats were challenged with OA and RL
was measured for 8 hours. The ER was calculated using the highest RL
9Iue during the first hour after antigen challenge. Bars represent the
.eans of each group.
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Figure 24B: Effect of pre-treatment with rhlL-5 on the Late Airway Response
8
7
6
5
4
3
2
1
o
Figure 24B: Effect of pre-treatment with rhlL-5 on the LR after antigen challenge.
Rats (n=23) were sensitized to OA and received either 3jg of rhlL-5 or BSA
intra-tracheally. Twenty hours later, rats were challenged with OA and RL
was measured for 8 hours. The LR was calculated as the area under the curve
for RL values obtained from 4 to 8 hours after antigen challenge. Bars represent
the means of each group
Control IL-5
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Figure 25: Effect of rhlL-5 on lung resistance 20 houts after antigen challenge
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Figure 25: Effect of rhlL-5 on lung resistance 20 hours after antigen challenge.
Rats (n12) were given 3 pg of rhlL-5 or BSA and challenged with QA 20
hours later. RL was measured 20 hours after antigen challenge in both groups
of rats. Bars represent the mean of each group. *p<O.O5 between IL-5 treated/
challenged and control groups.
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Figure 26: Effect of rhlL-5 on the airway responsiveness to Methacholine
20 hours after antigen challenge
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Figure 26: Effect of rhlL-5 on the airway response to Mch 20 hours after antigen
challenge. Rats (n19) were given 3 pg of rhlL-5 or BSA and challenged with saline
or QA 20 hours later. Twenty hours after OA or saline challenge rats were given
exponentially increasing doses of nebulized Mch until baseline RL doubled.
C200RL was calculated as the amount of Mch necessary to double RL. Bars
represent the mean of each group.
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Figure 27: Effect of rhlL-5 on lymphocyte subsets in the blood 8 hours after antigen
challenge. Rats (n=14) were sensitized with OA and received either 3pg of rhlL-5 or
BSA intra-tracheally.Twenty hours later, rats were chaflenged with OA. Peripheral
blood was recovered 8 hours after challenge and analyzed by flow cytometry for the( ercentages cf CD4 (helper) and CD8 (suppressor/cytotoxic) lymphocytes.
The CD4/CD8 ratio is presented for 7 rats in each group. *p<005 between IL-5
Figure 27: Effect of rhIL-5 on CD4ICD8 Lymphocyte ratio in the blood
8 hours after antigen challenge
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Discussion
The initiative for my doctoral thesis began by reflecting on a paper by Renzi et al. that assessed
whether the increase in airway narrowing by pre-treatment with IL-2 in EN rats was mediated by an
increase in leukotriene production (11). Cysteinyl-LT synthesis was evaluated by measuring the different
leukotriene metabolites in the bile by radioimmunoassay after purification by high-pressure liquid
chromatography. Bile has been previously shown to be the major route of excretion of cys-LT5
(302,303,304). Although IL-2 pre-treatment increased the early and !ate airway responses after OVA
challenge and enhanced airway inflammation, cys-LTs were Iower in IL-2-treated rats at baseline and
during the late response compared to controls, and this effect could not be explained by changes in cys
LT production or metabolism. Studies in humans, primates, and sheep that have looked at the release of
mediators from inflammatory celis have shown that cys-LT retrieval from the bile or from the lungs
increases during the late response and that selective antagonists of cys-LTs block the late response
(302,305,306,307). Therefore, it is undeniable that cys-LT5 have a role in the airway response to allergen.
I sought to explain these observed discrepancies in the IL-2 pre-treated BN rat mode!.
We began our investigation in this anima! mode! by studying the effects caused by IL-2-mediated
T ce!! activation. Although there is strong evidence that the allergic airway response can be modu!ated by
T lymphocytes, it is unclear which pathways are used. By designing an animal mode! protocol that
produced a state of heightened T ce!! activation, I hoped to see by what mechanism ce!! mediated
immunity may increase the late response. IL-2 is an important T ce!! growth factor that is released by T
lymphocytes in response to antigen presentation and !eads to lymphocyte activation, proliferation and
cytokine production fil). IL-2 and its receptor are increased in the lungs of asthmatic subjects (308). IL-2
is currently used in cancer therapy to activate immune effectors, such as T lymphocytes (309). Activated
T lymphocytes are present in the airways of patients with asthma and have been shown to correlate with
asthma severity as evidenced by the inverse correlation between CD25(IL-2)I CD4 cells and peak
expïratory flow rates (310). Not only are there increased numbers of “activated” CD25 (IL-2 teceptor)
bearing T helper celis in the peripheral b!ood of resting mi!d atopic asthmatics compared to normal
controls, this difference is even more pronounced during the deve!opment of exercise-induced
bronchospasm (310). In T ce!! cultures, IL-2 flot only induced CD25 (IL-2R) but also induced surface
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expression of several other activation-associated glycoproteins including 0X40, LFA-1, 57.1, 57.2, 1CR,
and CD4. This pleiotraphic activation led ta subsequent antigen reactivity in assays for T-ceII proliferation
(311). IL-2 aiso stimulates T lymphocytes from asthmatic subjects ta release mediators that increase
eosinophii proliferation and survival (312). Its administration ta human subjects causes easinophiiia
thraugh production af IL-5 (313). IL-2 has been shown ta increase infiammatory celis in the lung lavage,
namely macrophages, neutrophils and lymphocytes (11), therefore, it is capable af inducing pieiamorphic
inflammation.
This inflammation can have a multitude af effects an the airways and the iungs, therefore our first
experiment was ta test their sensitivity ta leukotrienes. In previaus studies performed on the BN rat, Renzi
et al showed that IL-2 pre-treatment caused an increase in the number of inflammatory celis present in
the BAL (10) and an increased airway response ta ovalbumin (10). Since the LR in BN rats and in
humans is related ta LTs (10), one might assume that leukotrienes wouid also be increased but as Renzi
et al. showed, cys-LTs were not increased in IL-2 pre-treated rats despite a LR (11). This observation
could be the resuit af the airways being mare sensitive ta Ieukotrienes. We tested this theory by
assessing the airway responsiveness ta LTD4 in IL-2 pre-treated and contrai rats. Dur resuits show that
rats pre-treated with IL-2 require a significantly Iower mean dose af LTD4 ta double baseline RL when
compared ta controls (p< 0.05) (Figure 14). We conclude that up-regulation of immune function with IL-2
increases the airway responsiveness ta LTs. The precise mechanism by which IL-2 alters the
responsiveness ta LTD4 is unclear. We have previously found a significant increase in BAL eosinophils
after pre-treatment with IL-2 compared ta untreated contrai animais that were challenged (10) or
unchallenged with antigen (OA) (11). In the experiments reported here, eosinophils were alsa increased
in IL-2 pre-treated rats after OA challenge when compared ta contrais. An increase in eosinophiis in the
airways may lead ta the release af more mediators such as eosinophii cationic pratein (ECP) (312) that
have the potentiai ta affect the airway responsiveness ta LTs. The tale of eosinophil-derived ptoteins in
branchial asthma is linked ta their ability ta injure the respiratory epithelium. (314,315,316). This cytotoxic
effect may then resuit in the loss of the functional integrity of the epitheiium and the exposure of mucosal
structures and sensory nerve endings, allowing the development of increased sensitivity af the airways ta
nonspecific bronchoconstrictor agents. Another cause of increased sensitivity ta LTs is the potentiai effect
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caused by IL-2 on Cys-LT1 receptors. Therefore our next experiment was to study the Cys-LT1 receptor in
our model.
The cysteinyl leukotrienes are known to cause airway smooth muscle contraction, which is a
direct function of airway responsiveness. The Cys-LT1 receptor is expressed in several tissues, including
human lung, human bronchus, and on human peripheral blood leukocytes including eosinophils,
neutrophils, monocytes, and T lymphocytes (317). It has been shown that airway smooth muscle cells
express a higher level of cytokine receptor mRNA and surface protein in the atopic asthmatic sensitized
state (318). IL-2 upregulates the production of cytokines that can increase surface receptors (319). It is
possible then that IL-2 increases the expression of the Cys-LT1 receptors on the surface of airway smooth
muscle celis hence an enhanced sensitivity to LTD4. Although oligonucleotide primers for the Cys-LT1
receptor gene have not been successfully synthesized at this time, future studies would include studying
the expression of this important receptor. However, IL-2 may also be exerting an effect at different points
along the signal transduction pathway of the Cys-LT1 receptor and not just specifically on the absolute
number of receptors. Activation of these receptors, which are coupled to G proteins, induces calcium
release that resuits in airway smooth muscle contraction (320). Nabata et al. have shown that vascular
smooth muscle cells pre-incubated with IL-2 had an increase in intracellular Ca2 and in DNA synthesis
when exposed to angiotensin Il (321). The Cys-LT1 receptot has been shown to have a calcium
mobilization response to the individual Cys-LTs. This signal appears to be the result of Ca2 release from
intracellular stores (322). Therefore, it is possible that IL-2 may potentiate the effects of LTD4 on the
airways by increasing Cys-LT1 receptor expression on airway smooth muscle andlor increasing the
activity of the signal transduction pathway.
In order to assess whether the cys-LTs were involved in the increased LR after pre-treatment with
IL-2, we administered the Cys-LT1 receptor antagonist, montelukast, at the Urne of OA challenge in rats
pre-treated with IL-2. The IL-2 induced LR was completely inhibited by montelukast (Figure 15). These
results show that LTs are not only involved in the LR but also in the increased airway response to OA
after pre-treatment with IL-2. The basis for Cys-LT activity in the lung may be due ta the site where its
receptor is located. The recently cloned Cys-LT1 receptor has been detected in human lung smooth
muscle ceils and lung macrophages (321 ,322). The identification of the Cys-LT1 receptor in the lung is
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consistent with the anti-branchoconstrictive actions af Cys-LT1 receptor antagonists such as montelukast
(322). It is therefore likely that IL-2’s effects on the LR occur through either an expansion of Cys-LT1
receptor expression in the lungs or an increase in the sensitivity of the receptor ta LTs as described
above. Besides the Cys-LT1 receptor, airway function can be modulated by countless other inflammatory
pathways. Our next experiment studied celiular and cytokine inflammation in the airways and Iungs of our
animal model.
Studies on the mechanisms of the LR have iinked ts pathophysiology to severai types of
inflammatory factors such as igE production, Thi and Th2 cytokine expression, and ceil influx (323).
However, the precise mechanism by which a LR occurs remains ta be determined. We studied BAL
inflammatory ceits and the expression of Thi and Th2 cytokine mRNA in the lungs of rats in order to
determine if any of these factors were affected by IL-2 treatment or by inhibition of the Cys LT1 pathway
with monteiukast. We found no statisticaliy significant difference in neutrophils, macrophages and
lymphocytes in the BAL between contrai and experimental groups of animais (Figure 16). Animais
chaiienged with OA and pre-treated with IL-2 showed a significant increase in BAL eosinophiis campared
ta the group of animais unchallenged and receiving saline (p<O.O5) (Figure 16). The former group of
animais alsa showed a LR, while the latter did not. This data supports resuits from previaus studies
indicating that eosinophils play an important raie in mediating a LR (324). Monteiukast administration
inhibited the IL-2-mediated LR withaut affecting the total number af ceils or differential in the BAL 8 haurs
after OA challenge. Althaugh there was a decrease in the number of BAL eosinaphils in the group af
animais that were pre-treated with IL-2 and received monteiukast, this difference was nat statisticaily
significant (Figure 16). Mantelukast has been shown ta have numetous effects on easinaphils. Virchow et
aI (325) showed that eosinaphii transmigration acrass cultured human umbilicai vein endothelial celis can
be blacked by montelukast. Moreover, LT receptor antagonists increased basal rates of eosinaphil
apoptasis and reversed GM-CSF-induced easînaphil survival (326). This is evidence af an autocrine
cysteinyl leukotrienes pathway that supports eosinaphii survival in response to a range of survivai stimuli.
Mantelukast has been shown ta reduce the percentage af easinaphils in the sputum and in the peripherai
bioad af mild asthmatics, but thete was no significant correlatian between this decrease and the abserved
increase in peak expiratary fiow (PEF). This suggests that mantelukast has anti-inflammatary effects on
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the airways of patients with asthma and that its bronchodilatory effect is flot soleiy dependant on a
decrease in airway eosinophilia (327). These results suggest that airway inflammation may be present
without any impact on airway tone (if LT activity is inhibited). However in a mouse model of asthma,
monteiukast had inhibitory effects on inflammatory celI infiltration in the bronchoalveolar lavage along with
a reduction in bronchial hyperresponsiveness (328). These inhibitory effects of montelukast suggest a
more important role for Cys-LTs in the animal model of allergic asthma.
We continued our investigation of this role by studying cytokine expression, specifically Thi and
Th2, in the lungs of our animal model. We assessed cytokine mRNA expression in the lung by using SQ
PCR and found that rats pre-treated with IL-2 had a significant increase in IL-4 and IL-5 mRNA (Th2)
(Figure 17N17B) and lower IFN-y mRNA (Thi) (Figure 17C) expression after OA challenge when
compared to animais given IL-2 and receiving montelukast at the time of challenge (p<O.05). Densometric
analysis allowed us to compare cytokine levels between groups in our study but their values cannot be
compared with other published literature. Therefore, the baseline levels of IL-4, IL-5 and IFN-y in our
control groups reflect only the expression of these cytokines in our animal model. These values indicate
that even without IL-2 treatment, control animais express IL-4, IL-5 and IFN-y in their lungs; findings not
unexpected since these cytokines are important mediators in numerous immunological pathways.
However, the differences in cytokine expression between control groups are flot significant.
The change in the balance between Thi and Th2 cytokine expression was also confirmed by in
situ hybridization. In situ hybridization tests revealed that ceils expressing IL-4 mRNA were more
predominant (Figure 18A) and ceils expressing IFN-y mRNA were Iess predominant (Figure 18B) after
pre-treatment with IL-2 and OA challenge. Interestingly, these changes are similar to those described
previously in the EN rat or in humans when a LR occurs (329). IL-2 effector functions have been iinked to
Th2 cytokine activity, specificaily Youn et aI (330) showed that transgenic mice which have expression of
a chimeric cytokine receptor (extracellular: IL-2R13 chain, cytoplasmic tau: IL-4RŒ) dramatically enhanced
Th2 responses (IL-4, IL-5, and IgE production) upon in vitro 1CR stimulation or in vivo antigen challenge.
This augmented 1h2 effector function is sufficient for establishment of antigen-induced airway
hyperresponsiveness on a normally disease-resistant background (C57BL16). The addition of montelukast
at the time of QA challenge lead to a predominance of cells expressing the Thi cytokine, IFN-y and less
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celis expressing IL-4 and IL-5 mRNA as described in rats that do not develop e LR (301). Previous
studies showed a similar effect by montelukast on Th2 cytokines. Stelmach et aL (331) demonstrated that
montelukast contributes to inhibition of allergic inflammation by decreasing serum IL-4 levels in
correlation with improvements in clinical parameters (symptoms score, FEV1), bronchial
hyperresponsiveness in children with moderate asthme. A separate study by Henderson et al (332)
showed that montelukast inhibited IL-4 and IL-13 mRNA in lung tissue and protein in BAL fluid in OA
treated mice. These data demonstrate that montelukast can reverse the effects of IL-2 and OA challenge
on Thl-Th2 cytokine mRNA expression.
Many studies have shown the important role of cytokines in asthma (333). IL-4 can Iead to
selective recruitment 0f inflammatory celis such as mast cells and eosinophils as well as inducing the
production of IgE from B cells (334). IL-5 is involved in recruiting and activating eosinophils, ceils that
release mediators with the potential of causing several changes that are found in asthma such as
bronchoconstriction, inflammation and epithelial ceil desquamation (327). Th2 cytokines have been
shown to be increased in the Iungs of atopic asthmatics (335). Venkayya et aI (336) showed that Th2
cytokines might induce AHR by acting directly on resident airway cells. Th2-Iymphocyte-conditioned
medium administered to the airways induced AHR within 6hr in naive mice. However, AHR was not
induced when mice Iacked the IL-4 receptor alpha subunit or Stat6, suggesting a critical role for IL-4
and/or IL-13. The induction of AHR occurred in the absence of inflammatory celi recruitment or mucus
production. IFN-y is a Thi cytokine that may inhibit certain effects of Th2 cytokines (318). The role that
cys-LT5 play in modulating the balance between Thi and Th2 cytokines has not been previously
assessed. A recent study by Hasday et al. showed that asthmatics with high cys-LTs production in the
BAL 24 hours after segmental ragweed challenge also had increased IL-5, IL-6, and TNF-a production
compared to 10w cys-LT5 producers (337). This indicates that cys-LIs production may have a direct
relationship with cytokine production. Recently, numerous studies have pointed to an important Iink
between cytokines and the Cys-LT pathway. For example, Thivierge et al. (338) showed that IL-5
upregulated the Cys-LT1R expression on a differentiated eosinophfl celi me. Consequently, receptor
function on these eosinophils is also augmented, namely enhanced responsiveness and chemotactic
response to LTD4. This same group showed a similar relationship between cytokines and the Cys-LT
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pathway in monocytes and macrophages (339). However, in this case, the Th2 cytokines, IL-4 and IL-13,
upregulated the expression and function of the cys-LT1 receptor. These ceils also showed enhanced
responsiveness and chemotactic activity to LTD4, indicating a possible mechanism through which IL-4
and IL-13 can contribute to the pathogenesis of asthma. Leukotriene D4 has also been shown to influence
cytokine production from alveolar macrophages (AM) (340). LTD4 primes AM by causing an increase of
mRNA for MIP-la and TNF-a and when further stimulated with LPS resulted in e release of MIP-la, TNF,
and NO. This is evidence of LTD4’s ability to potentiate the production of proinflammatory mediators by
AM during immunologic stimuli. Moreover, it has recently been established that the cys-LT1 receptor is not
only expressed on the smooth muscle cells of the airways, but that there is also a high expression of the
receptor on peripheral blood lymphocytes (PBL) (320), suggesting that cys-LTs have an effect on T
lymphocyte function. The Cys-LT1 receptor has also been found on human mast cells. Mellor et aI. (341)
not only identified the receptot on mast cells but also showed that the receptor responds to cys-LTs and
the pyrimidinergic ligand, UDP. The threshold of responsiveness to these agonists was lowered after
priming of the mast ceNs with IL-4 for 5 days. This enhanced sensitivity was accomplished without altering
Cys-LT1 receptor mRNA or surface protein expression, suggesting the Iikely induction of a second
receptor with Cys-LT1-like dual Iigand specificity. Evidence of such a receptor has not been observed yet,
but this theory could explain how rats in our study are more sensitive to LTs after IL-2 treatment without
an increase in LTs production. The results presented here suggest that cys-LTs are involved in mediating
cytokine production affer OA challenge because montelukast was able to change the profile 0f Thi and
Th2 mRNA expression. The mechanism by which the LT pathway affects cytokine mRNA production has
not been explored.
In this animal mode!, it is clear that LTs along with inflammatory cells and cytokines play an
important role in mediating a bronchopulmonary response. Allergen challenge of sensitized animaIs
causes the activation and recruitment into the airways of a variety of cells, including eosinophils,
lymphocytes, mast cells, and neutrophils (342, 300, 343). These inflammatory celis are involved in the
physiological and pathological changes that are present in atopic asthme (296). The mechanism by which
these changes occur are flot clear. However resuits from this study so far suggest that the cytokine IL-5
may be an important modulator of allergic inflammation. Studies to date have shown IL-5 to be increased
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in the blood and Iungs of patients with asthma (344) and that administration of IL-5 to patients with
allergic bronchiai asthma increases cholinergic responsiveness and the number of activated eosinophils
in the airways (7). Studies in animais have shown that administration of IL-5 to sensitized guinea pigs
enhances antigen-induced hyperresponsiveness (345) and that IL-5 neutralizing antibodies inhibit the late
phase response after antigen challenge (346). Aithough there is convincing evidence that IL-5 is
important in asthma and in animal modeis of asthma, no study has studied the effects of IL-5 alone in a
nonasthmatic animal model, namely in animais that do flot respond to sensitization and antigen challenge
with early and late-phase responses. We performed this study in the SSN substrain of BN rat that does
not develop an ER or LR after antigen challenge (285, 347) in order to assess whether IL-5 has the
capacity to transform non-responsive BN (SSN) rats into those with the characteristics encountered in
atopic asthma.
We first determined whether recombinant human IL-5 (which has 71% homology with rat IL-5
(346)) had effects on rat blood ceils in vitro. Experiments performed on rat PBMNC showed that rhIL-5
caused a concentration-dependent proliferation of eosinophils from progenitors at a dose ranging from I
to 5 ng/ml (Figure 19). We also determined if the BN rat model was actively sensitized to QA by
measuring levels of OA-specific IgE for I to 3 weeks following sensitization. Rats showed a significant
increase in serum QA-specific IgE for at least 3 weeks following QA sensitization (Figure 20). We then
determined whether intra-tracheal administration 0f rhIL-5 had effects on airway responsiveness to Mch.
An increase in airway responsiveness to Mch occurred 20 hours after intra-tracheal administration of rhiL
5 at a dose of 3 pg or more (Figure 21). Recombinant human IL-5 did not affect airway responsiveness
30 minutes or 72 hours after intra-tracheal administration (Figure 22). The fact that airway
responsiveness to Mch occurred at 20 hours and not at 30 minutes or 72 hours following IL-5
administration suggests that IL-5’s effects on the airway s mediated thru an indirect pathway. It has been
shown that in guinea pigs, inflammatory celi numbers in the tissues peak at or before 24 hours following
IL-5 administration (298) and return to baseline over 6 days. Resuits obtained from lung lavage in our
animais would concur with this study. We found a dose-dependent increase in the total cellular return,
which consisted mainly in neutrophils, from the lung lavage. We measured the level of endotoxin in the
rhIL-5 given to animais, and to be certain that this low level of endotoxin was not affecting the results we
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administered the same dose of LPS intra-tracheally to animais and measured their airway response to
Mch and inflammatory celis in the BAL 20 houts ater. Data collected from animais given LPS did flot
differ significantly with controis, therefore we were confident that the effects af rhiL-5 wete flot due to
endotoxin contamination. We aiso performed additional experiments confirming the direct effect of rhlL-5
by using TRFK5, an IL-5 neutralizing antibody. Addition of 5Ong of TRFK5 to lOpg of rhlL-5 significantiy
reduced airway responsiveness and ceil influx after OA challenge when compared to the groups that
received only lOpg of rhIL-5. Ihe type of celI influx in our IL-5-treated animais was particularly interesting.
We decided to furthur understand the discrepancy between our results and pubiished ilterature.
Our celI influx experiment showed that IL-5 caused an increase in BAL neutrophiis 20 hours post
administration, but flot in eosinophils as has been described in guinea pigs (298). This discrepancy may
be due to the inherent differences between the two animai models. BN SSN rats may flot have had an
increased number of eosinophils in lung lavage because of technical considerations. Van Rensen et al.
(348) administered IL-5 intravenously and by inhalation to mild asthmatics and showed an increase in
blood eosinophils without any effect on eosinophil mobilization in the lungs or on bronchial
respansiveness in either group. Moteover, eosinophil degranulation and mediator release may have
aiready taken place 20 hours aher IL-5 administration preventing us from measuring their presence by a
reguiar Wright-Giemsa stain. However, we obtained the same resuits when we employed MBP staining
which adds more probability to the conclusion that eosinophils were not increased in lung lavage 20 hours
after IL-5 administration. Another reason for this discrepancy is that perhaps eosinophils are unavailable
for recruitment into the lungs in this strain of rat. Until now, experiments assessing whether IL-5 is
involved in asthma have employed animai madels that deveiap ailergic responses after antigen challenge
and have shown that the physiologicai response can be increased by IL-5. It is possible that in “atopic’
animai modeis, eosinophils or their progenitors are readiiy available to be recruited into the lungs
whereas in BN SSN rats these ceils are not avaliabie. Certain studies daim that eosinophils do flot play
an important raIe in bronchoconstriction. In vitro studies of the human smooth muscle response ta IL-5
showed enhanced responsiveness independant of eosinophiis (349). Severai studies over the last yeat
have shown that certain therapies that reduce eosinophil numbers do not lead ta clinical improvement of
asthma (350). Researchers are now questioning the tale of eosinophils in allergic inflammation. Other
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inflammatory celis may have more important roles than previously thought; such as neutrophils which
release products foxygen radicals, proteases, and cationic proteins) that have the potentiai for altering
airway function by causing tissue injury (351). Therefore, aithough the SSN strain of BN rat may not
respond to IL-5 with increased eosinophil accumulation into the airways, increased responsiveness to
Mch 20 houts post-IL-5- administration may have stili occurred through neutrophil degranulation.
Having studied the effects of administering IL-5 aione in our animal model, we decided to
continue studying the effects of IL-5 on animais challenged with antigen, which causes higher IgE
production. Could IL-5 cause a physiological change in the Iungs of these animais perhaps ieading to an
ER, LR, or AHR? Pre-treatment of guinea pigs with IL-5 has been shown to induce lung eosinophiiia and
bronchoconstriction after antigen challenge (8). As weII, administration of a monoclonal anti-IL-5 antibody
to sensitized guinea pigs inhibits both BAL eosinophilia and airway responsiveness after DA challenge
(352). We assessed the effects of pre-treatment with rhIL-5 on the ER (Figure 23A), LR (Figure 23B),
and AHR in BN SSN rats that do not have a physiological response after sensitization and QA challenge.
Intra-tracheai administration of 3pg of rhIL-5, 24 hours prior to QA challenge, did flot affect the ER, LR, or
cellular influx after challenge when compared to controls receiving the same amount of BSA. It may be
that in the predisposed subject, intra-tracheal IL-5 is capable of increasing aIl the physioiogical changes
that occur after antigen challenge, but that several crucial factors that are necessary for an atopic airway
response may be lacking in the normal rat. These include the presence of inflammatory cells, certain
chemokines (eotaxin, MCP-4) or of other cytokines (GM-CSF) (353,354). Although these animaIs did not
produce an ER or LR after IL-5 treatment and Ag challenge, their Iungs could stiil be susceptible to
surface changes.
We measured these surface changes by calculating the animais’ lung resistance and AHR 20
hours after Ag challenge. We chose these parameters becauses physiologicai changes that occur after
antigen challenge also include airway obstruction and increased cholinergic airway responsiveness. We
first tested the efficacy of our sensitization protocol by giving a group of non-sensitized rats a 3 pg dose of
IL-5 followed 20 hours later by an OA challenge. Lung resistance was not significantly different from the
control group of animais that were sensitized and given BSA instead of IL-5. However, pre-treatment of
sensitized rats with IL-5 increased baseline lung resistance measured 20 hours after OA challenge
103
(Figure 24). IL-5 had no effect on airway responsiveness to Mch (Figure 25). The changes in airway
resistance can be linked to various immunological events including T celi activation, IL-4 production, IgE
synthesis and mediator release by effector ceils such as eosinophils and mast cells (355). In our study,
we found a significant decrease in the CD4ICD8 T celI ratio in the blood between IL-5 pre
treated/challenged and control animaIs 8 hours after antigen challenge (Figure 26). The difference is
mainly due to an increase in CD8 cytotoxic/suppressor T cells in the blood of challenged animais. A
decrease in the helper/suppressor ratio in the biood has been described during the LR in humans (296). It
has been postulated that CD4 lymphocytes are recruited into the lungs after antigen challenge in the
subjects that develop a LR. This hypothesis has been predicated upon the finding of increased CD4 ceils
in lung lavage after antigen challenge (355). We have previously reported a decrease in the
helper/suppressor ratio in the blood of BN rats that develop a LR (300). lnterestingly, pre-treatment with
IL-5 induced the same changes in the CD4/CD8 ratio as those previousty reported in BN rats with LR.
However, it is not clear how IL-5 modulates the CD4ICD8 T cell ratio in the biood of the rats. The absence
of a LR in the IL-5 pre-treated rats would suggest that changes in blood lymphocyte subsets is not
sufficient in mediating a LR. Although blood lymphocyte subsets were not significantly different between
groups, we were interested in studying the possible changes in cytokine production from these
lymphocytes.
In our search to find a possible mechanism by which IL-5 could increase RL 20 hours after QA
challenge, we assessed lung Thi and Th2 cytokine mRNA expression. We found increases in both IL-4
and IL-5 mRNA expression after antigen challenge but no effect on the Thi cytokine IFN-y mRNA
expression. Increases in Th2 cytokines are associated with increases in lung resistance affer antigen
challenge in humans (356). Lee et al measured cytokine levels by ELISA in the serum of acute
asthmatics and found higher leveis of IL-4, IL-5, and IL-13 (356). They also associated higher leveis of IL
5 and lower levels of IFN-y with severe airway obstruction. Therefore, it is possible that the effects in RL
encountered in OA challenged BN rats are explained by changes in these cytokines. These cytokines
may act by recruiting and/or degranulating inflammatory cells in the Iungs following antigen challenge.
Our next experiment measured the levels of an important inflammatory ceil, eosinophils, in the BAL of our
animais.
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IL-5 administration followed by allergen challenge has been shown to increase eosinophil
numbers in lung tissue and increase AHR (7). However, in our study there was no observed increase in
AHR to methacholine following IL-5 treatment/OVA challenge. It is possible that the increased RL in IL-5
pre-treated rats masked the effects on AHR. Perhaps other factors are necessary for AHR to occur after
antigen challenge in the BN SSN rat. Factors such as increased CD4 T ceIl activation, higher IgE levels,
the presence of more eosinophils, cytokines such as TNF-Œ, GM-CSF, immunoglobulins, and chemokines
such as eotaxin and RANTES may be necessary for AHR to occur. In addition, certain characteristics of
celis that constitute normal lung tissue i.e. epithelial ceils and smooth muscle celis may also be lacking in
the BN SSN rat for AHR to occur after antigen challenge.
Conclusion
We have confirmed previous resuits in rats and in guinea pigs that show up-regulatïon of cellular
immunity with IL-2 increases the airway response to antigen. Moreover, IL-2 does not increase LT
production in this animal model following antigen challenge, but it can enhance the sensitivity of the
airways to Cys-LTs. Further investigation led to the discovery of a link between LTs and Thl/Th2 cytokine
production. Taken together, the first part of my thesis shows a link between cell-mediated immunity and
leukotrienes in an animal model of asthma.
We then proceeded to assess whether one important cytokine could reproduce ail the changes
that are found in asthma by assessing the effects of IL-5 in BN SSN rats that do flot develop ER and LR
after sensitization and antigen challenge. We found that intra-tracheal administration of rhlL-5 to rats that
do not have the characteristics of atopic asthma will cause some but not aIl of the cellular and
physiological changes that are found in atopic asthma. As suggested in a recent publication (357),
therapeutic strategies directed against IL-5 alone may be insufficient to revert the airway response to
normal in atopic asthmatics. Although preliminary data from the first clinical trials give rise to skepticism
about the efficacy of anti-IL-5 treatment regard ing the improvement of lung function of asthmatic patients,
further studies with a better defined profile of the target population may provide encouraging resuits.
A synthesis of the results from both parts of thesis leads to the general conclusion that asthma is
a heterogeneous disease. On one hand, Cys-LTs are clearly an important mediator in the asthma
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phenotype, with our data showing that it can cause the late response and promote Th2 cytokines. But on
the other hand, IL-5, considered a key mediator in asthma, according to out data has limited impact on
asthma development. Therefore, the overall message is that there is no single cause of asthma, rather
multiple interacting proinflammatory mechanisms, each with varying levels of consequence on the
airways.
Future Perspectives
The discovery of the ptocesses underlying the inflammatory response in the lung and theit control
mechanisms is a long and winding road that many scientists take. This project has managed to shed light
on parts of this road, however much work remains. In order to add more weight to the theories, future
studies are needed to quantify the expression of the Cys-LT1 receptor in our animal mode!. Moreover, a
complete analysis of other important inflammatory markers such as chemokines (particularly CCR3), and
cytokines (ex: IL-13, IL-8) must be done. It would also be important to see if our resuits (name!y
immunomodulation of Thi and Th2 cytokines) could also be duplicated in asthmatics currently being
tteated with montelukast. The cytokine Interleukin-5 was once considered an important mediator due to
its effects on eosinophils. However unsuccessful anti-IL-5 therapies have persuaded scientists that it is
flot the magic bullet for curing asthma. If we acknowledge that the causes of asthme are multifactorial, a
multiple anti-cytokine therapy, including anti-IL-5, is a potentially effective means to combat the disease.
While this study adds to the wealth of knowledge on immunomodulatory function, specifically in asthma,
the scientific community continues to strive to identify specific targets for therapeutic measures that are
designed to impede or abolish the allergic inflammatory cascade.
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